



Review Article

Interaction of neurotransmitters and neurochemicals with lymphocytes

Daniel Kerage^{a,b}, Erica K. Sloan^{c,d,e}, Stephen R. Mattarollo^a, Pamela A. McCombe^{f,g,*}^a The University of Queensland Diamantina Institute, Brisbane, Australia^b Transplant Research Program, Boston Children's Hospital, Boston, MA, United States of America^c Drug Discovery Biology Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia^d Division of Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia^e Cousins Center for Neuroimmunology, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles, USA^f The University of Queensland Centre for Clinical Research, Royal Brisbane and Women's Hospital, Brisbane, Australia^g Royal Brisbane and Women's Hospital, Herston, Brisbane, Australia

ARTICLE INFO

Keywords:

Neurotransmitters

Lymphocytes

Neural signaling

Immune regulation

Immunomodulation

ABSTRACT

Neurotransmitters and neurochemicals can act on lymphocytes by binding to receptors expressed by lymphocytes. This review describes lymphocyte expression of receptors for a selection of neurotransmitters and neurochemicals, the anatomical locations where lymphocytes can interact with neurotransmitters, and the effects of the neurotransmitters on lymphocyte function. Implications for health and disease are also discussed.

1. Introduction

Cells of the nervous system communicate with each other by means of chemical messengers, termed neurotransmitters, that move across synapses to activate receptors on postsynaptic cells (Wilkinson and Brown, 2015). The brain also produces molecules (called neurochemicals) that act on receptors but do not fulfil the criteria for neurotransmitters. Since immune cells express receptors that can be stimulated by these neurotransmitters and neurochemicals, the nervous system can influence the function of lymphocytes.

Communication between the immune system and the nervous system is two-way: lymphocytes also produce signaling molecules including cytokines that can affect the nervous system (Chavan et al., 2017). Bidirectional communication between these systems allows fine-tuning of the homeostatic response to a changing environment (Sloan and Walker, 2019). However, this review focuses on the interaction of neurotransmitters and neurochemicals with lymphocytes. We also review how modulation of lymphocytes by neurotransmitters and neurochemicals may be leveraged for disease treatment, and explore how drugs that influence neurotransmitters could affect human health.

2. Neurotransmitters and neurochemicals

A neurotransmitter must meet four criteria (Orrego, 1979). Firstly, it must be synthesized in neurons. Secondly, it will be present in the

presynaptic terminal and released in amounts sufficient to exert a defined action on the postsynaptic neuron or target cells in effector organs. Thirdly, exogenous administration should mimic the action of the endogenously produced neurotransmitter. Fourthly, intrinsic mechanisms exist for its removal from its site of action. Neurotransmitters can be (a) biogenic amines including serotonin, dopamine, epinephrine (adrenaline), and norepinephrine (noradrenaline), (b) neuropeptides including substance P, and (c) amino acids including glutamate and γ -aminobutyric acid (GABA) (Kavalali, 2015; Orrego, 1979; Rangel-Gomez and Meeter, 2016; Wilkinson and Brown, 2015). Here, we review a selection of neurotransmitters that modulate immune function (see Table 1). We also review endocannabinoids and endorphins because these systems are frequently subject to pharmacological manipulation with possible physiological consequences for immune regulation, and adenosine which is important at the intersection of metabolism with the immune systems.

3. Where do lymphocytes come into contact with neurotransmitters and neurochemicals?

As defined above, a neurotransmitter must be produced by neurons. Lymphocytes can be exposed to neurotransmitters in the blood or tissue. T-cells entering the central nervous system (CNS) encounter neurotransmitters at the site of release from neurons. Neurotransmitters are also found in blood. For example, acetylcholine can be detected in

* Corresponding author at: The University of Queensland Centre for Clinical Research, Royal Brisbane and Women's Hospital, Brisbane, Australia.

E-mail address: pamela.mccombe@uq.edu.au (P.A. McCombe).

Table 1
Neurotransmitter and neurochemical receptors on immune cells and strategies for therapeutic intervention.

Name	Receptors identified on lymphocytes	Immune cell targets	Possible modifying drugs	References
Epinephrine & norepinephrine	Adrenergic	Macrophage, monocyte, dendritic cells, natural killer cells, T lymphocytes, B lymphocytes	Beta blockers, adrenergic drugs	(Wu et al., 2018)
Dopamine	D2, D3, D4 and D5	Macrophage, natural killer, T lymphocytes, B lymphocytes	Anti-psychotics and Parkinsons disease drugs	(Talhada et al., 2018)
Acetylcholine	Muscarinic and nicotinic	Macrophage, dendritic cells, T lymphocytes, B lymphocytes	Cholinesterase inhibitors	(Fuji et al., 2017a)
Glutamate	mGluR1, mGluR5, AMPA, NMDA	Dendritic cells, T lymphocytes	AMPA agonists (for epilepsy), NMDA receptor antagonists (for psychosis)	(Fallarino et al., 2010)
GABA	GABA _A (plus others)	Monocyte, macrophage, neutrophil, T lymphocytes, B lymphocytes	GABA agonists (for spasticity, anxiety, anesthesia)	(Jin et al., 2013)
Serotonin	5HT1, 5HT1A, 5HT1B, 5-HT2A, 5-HT3, 5-HT3A and 5-HT7	Macrophage, dendritic cells, eosinophils, platelets, T lymphocytes, B lymphocytes	Anti-depressants, migraine medications	(Herr et al., 2017)
Substance P	NK1	Macrophages, T lymphocytes, B lymphocytes	NK1 agonists (used as anti-emetic)	(Mashaghi et al., 2016)
CGRP	CGRP receptor	Antigen presenting cells, mast cells, T & B lymphocytes	Anti-CGRP monoclonal antibodies	(Assas et al., 2014; Holzmann, 2013; Mikami et al., 2011)
Endocannabinoids	CB2	Macrophages, mast cells, activated T lymphocytes, B lymphocytes	Medical and recreational cannabis	(Chiruchiu, 2016)
Endorphins	μ, δ, κ	Monocytes, dendritic cells, natural killer cells, T lymphocytes, B lymphocytes	Medical use, narcotic abuse	(Bidlack, 2000)
Adenosine	A2A	Macrophage, dendritic cells, neutrophils, mast cells, T lymphocytes	Adenosine receptor antagonists (in development)	(Hasko et al., 2008)

blood (Watanabe et al., 1986), as can catecholamines (Yamaguchi and Kopin, 1979) and CGRP (Tfelt-Hansen and Le, 2009). Levels of substance P are increased in the blood after stroke (Lorente et al., 2016) and endocannabinoid levels in plasma are increased with exercise (Thompson et al., 2016). As well as being produced by neurons, neurotransmitters and neurochemicals are produced by other cells, including lymphocytes (Chen et al., 2015; Cosentino et al., 2007; Mossner and Lesch, 1998; Orrego, 1979; Wilkinson and Brown, 2015), resulting in both autocrine and paracrine action on immune cells (Rangel-Gomez and Meeter, 2016).

Primary (thymus, bone marrow) and secondary (lymph nodes, gut and spleen) lymphoid organs are innervated by nerves. These nerves release neurotransmitters that interact with lymphocytes (Bellinger et al., 1993; Bellinger et al., 2008; Calvo, 1968; Felten and Felten, 1988; Felten et al., 1993; Fink and Weihe, 1988; Nance and Sanders, 2007) {Nance, 2007 #8843}. Such innervation contributes to the development of immune cells (Bellinger et al., 2008). The dopaminergic reward system of the brain also influences immunity (Ben-Shaanan et al., 2016) as do nociceptive pathways that play a role in the integration of the immune and neural responses to injury (Pinho-Ribeiro et al., 2017). The locations where the nervous system affects the immune system are now discussed.

(A) INNERVATION OF THE BONE MARROW: The sympathetic nervous system (SNS) provides the major nerve supply to the bone marrow (Calvo, 1968; Felten et al., 1985; Weihe et al., 1991) and regulates the production and release of lymphocytes (Ueda et al., 2005, Webber et al., 1970, Katayama et al., 2006).

(B) INNERVATION OF THE THYMUS: The thymus is innervated by the SNS (Nance et al., 1987; Tollefson and Bulloch, 1990). SNS nerve fibers enter through the perivascular network, and branch into the deep cortical region, upper cortical and subcapsular regions, septa, cortico-medullary junction and medulla (al-Shawaf et al., 1991; Mignini et al., 2003). Noradrenergic innervation of the thymus has been demonstrated through tyrosine hydroxylase (TH) staining (Vizi and Elenkov, 2002), with high density of nerve fibers near the cortico-medullary junction and less in the subcapsule and cortex area (al-Shawaf et al., 1991; Cavallotti et al., 1999). Activation of β-adrenergic receptors by norepinephrine released from SNS nerves has inhibitory effects on the maturation, proliferation and differentiation of thymocytes (Leposavic et al., 2011; Madden and Felten, 2001).

(C) INNERVATION OF THE SPLEEN: The prevertebral sympathetic ganglia that are associated with the celiac-superior mesenteric plexus innervate the spleen. This neural network extends to the white and red pulp, and marginal zone with nerve endings in close proximity to splenic T cells, B cells and dendritic cells (DCs) (Ackerman et al., 1987; Bellinger et al., 1987; Felten et al., 1987; Felten et al., 1985). Studies so far have found only sympathetic innervation of the spleen (Felten et al., 1987; Felten and Olschowka, 1987; Nance and Sanders, 2007; Straub, 2004).

(D) INNERVATION OF THE LYMPH NODES: SNS fibers enter the hilus of lymph nodes along with blood vessels, run along the vascular and lymphatic networks in the medulla, paracortex and cortical regions (Felten et al., 1984; Fink and Weihe, 1988), and branch into the T cell zones in the parenchyma of the medulla and paracortex (Novotny and Kliche, 1986). The SNS does not innervate the B cell-rich germinal centers (Felten et al., 1984; Sloan et al., 2007). SNS neural networks in lymphoid organs are in close contact with immune cells and regulate the immune response (Sloan et al., 2007; Sloan et al., 2006).

(E) NOCICEPTIVE PATHWAYS: Nociceptive pathways include the peripheral nerves that respond to noxious stimuli (Dubin and Patapoutian, 2010) and the central nervous system pathways that are activated by these peripheral nerves. Nociceptive nerves release specific neurotransmitters that can influence the immune system (Pinho-Ribeiro et al., 2017; Ren and Dubner, 2010).

(F) CNS PATHWAYS: There is growing understanding that the brain regulates neural signaling to immune cells in peripheral organs. The

ventral tegmental area (VTA) is the brain reward system involved in pleasure and incentive salience, as well as response to stress (Dutcher and Creswell, 2018; Kasanova et al., 2017). The VTA is connected by the mesolimbic pathway to the nucleus accumbens, the amygdala and the prefrontal cortex (Richard et al., 2013). This system drives behaviors such as eating and reproduction. In disease, the brain reward system is linked to addiction, gambling and obesity. The brain reward system stimulates innate and adaptive immunity through modulation of the sympathetic nervous system (SNS) (Ben-Shaanan et al., 2016; Ben-Shaanan et al., 2018).

4. Interaction of neurotransmitters and neurochemicals with lymphocytes

4.1. Epinephrine and norepinephrine

Epinephrine is a hormone and neurotransmitter that is produced by the adrenal medulla and neurons (Wood, 2006). The splanchnic sympathetic nerve controls the release of epinephrine from the adrenal medulla (de Diego et al., 2008; Esler et al., 1988; Esler et al., 1990). Norepinephrine is produced in brainstem nuclei, by sympathetic nerves within organs and by the adrenal gland. The main source of norepinephrine is nerve terminals of the post-ganglionic SNS (Eriksson et al., 1996; Furlan et al., 2016). Peripheral blood mononuclear cells (PBMC) also synthesize catecholamines, including epinephrine, norepinephrine and dopamine, and their metabolites (Bellinger et al., 2008; Elenkov et al., 2000; Scheiermann et al., 2012). Activation of the tyrosine hydroxylase pathway stimulates the synthesis of dopamine, which leads to production of norepinephrine and epinephrine. Adrenocorticotrophic hormone (ACTH) stimulates the adrenal cortex leading to increased production of cortisol, which enhances epinephrine biosynthesis (Sneader, 2001; Wood, 2006). The main physiologic triggers of epinephrine and norepinephrine release are perturbations of physiological homeostasis, such as physical threat, noise exposure, psychological stress or change in temperature. Circadian rhythm also has an impact on immune function through the SNS (Scheiermann et al., 2013). Epinephrine and norepinephrine have physiologically important effects on metabolic activity, blood flow to muscles and cardiac output. Norepinephrine regulates the circadian rhythm, dreaming and learning (Wood, 2006).

Epinephrine and norepinephrine induce their activity by binding to α - and β -adrenergic receptors (Burn et al., 1950). Adrenergic receptors are expressed on immune cells including T cells and B cells, macrophages and NK cells, β_2 -adrenergic receptor the dominant sub-type on most immune cells (Bergquist et al., 1994; Cosentino et al., 2007).

By binding to adrenergic receptors, epinephrine and norepinephrine regulate immune activity (Sneader, 2001; Wood, 2006). Signaling through β_2 -adrenergic receptors on lymphocytes regulates cellular trafficking from lymphoid organs (Bellinger et al., 2008; Elenkov et al., 2000; Nakai et al., 2014). Lymphocyte trafficking from lymph nodes is dependent on sphingosine-1-phosphate receptor-1, and occurs when retention signals mediated by the chemokine receptor CCR7 are overcome (Nakai et al., 2014; Pham et al., 2008). Activation of lymphocyte β_2 -adrenergic receptors promotes CCR7-dependent retention signals, thereby inhibiting lymphocyte egress from lymph nodes and preventing lymphocyte migration to inflamed tissues. The SNS directly innervates lymphoid tissues and the release of norepinephrine from nerve terminals controls recruitment of myeloid cells into tissues by modulating the expression of adhesion and chemo-attractant molecules by vascular endothelial cells (Scheiermann et al., 2012). Adrenergic signaling in immune cells modulates inflammation by regulating cytokine production. Initial upregulation of pro-inflammatory cytokines including IL1 β and TNF α (Porterfield et al., 2012; Scanzano and Cosentino, 2015) is modulated by upregulation of IL10, which dampens pro-inflammatory signaling (Agac et al., 2018).

Activation of the SNS has been linked to diseases, in part due to

inhibition of T_H1-mediated inflammation and impaired CD8 T cell-mediated adaptive immunity, and a shift to enhanced T_H2 responses (Elenkov et al., 2000; Marino and Cosentino, 2013). In multiple sclerosis, β_2 adrenergic receptors are increased in peripheral mononuclear cells (Arnason et al., 1988; Zoukos et al., 1992) and in experimental autoimmune encephalitis, increasing norepinephrine leads to reduced severity (Simonini et al., 2010). In rheumatoid arthritis there is a decrease in density and affinity of β_2 -adrenergic receptors on peripheral mononuclear cells such as CD8 T cells and B cells (Baerwald et al., 1997; Wahle et al., 2001). This is seen particularly on cells in synovial fluid, which means that these lymphocytes are less responsive to the suppressive activities of catecholamines (Baerwald et al., 1997) leading to increased tissue damage (Wahle et al., 2006). However, in chronically inflamed joints, it has been suggested that the end result is zones of inflammation that are cut off from regulation by the SNS, so that inflammation is ongoing (Pongratz and Straub, 2014).

In cancer, SNS signaling impairs anti-cancer immune responses and increases tumor cell invasion to accelerate cancer progression and metastasis (Bucsek et al., 2017; Nissen et al., 2018; Scheiermann et al., 2013; Sloan et al., 2010). These studies suggest that immune responses could be controlled through pharmacological interventions that stop catecholamine signaling through β -adrenergic receptors.

4.2. Dopamine

Dopamine is produced in the brain (Klein et al., 2019; Wang et al., 2009) and by sympathetic nerves that innervate secondary lymphoid organs. Dopamine has also been identified in different immune cell populations including CD4⁺CD25⁺ regulatory T cells, granulocytes, T and B cells (Cosentino et al., 2007; Levite, 2008). Dopamine acts on G-protein-coupled receptors (D1–D5) to regulate biological effects including control of movement, emotion, cognition, cardiovascular and endocrine functions (Levite, 2008; Missale et al., 1998). Dopamine receptors are expressed by human and mouse lymphocytes (Alberio et al., 2012; Levite, 2016; Mignini et al., 2013; Pacheco et al., 2009). Binding of dopamine leads to reduced cAMP levels in stimulated lymphocytes (Santambrogio et al., 1993).

Dopamine has effects on lymphocyte proliferation and differentiation (Bergquist et al., 1994; Pacheco et al., 2014). These effects are dependent on the dopamine receptors expressed (e.g. D2–5), T cell subtype, T cell activation status and dopamine concentration (Levite, 2008; Levite et al., 2001; Santambrogio et al., 1993). D3 is preferentially expressed on naïve CD8 T cells (Watanabe et al., 2006). Highly selective agonists targeting dopamine D2 and D3 receptors on T cells enhance T cell adhesion to fibronectin by sensitizing $\alpha_4\beta_1$ and $\alpha_5\beta_1$ integrins (Levite, 2008, 2016; Levite et al., 2001). Such T cell adhesion is important for trafficking and extravasation of T cells following tissue injury or infection (Levite et al., 2001). By working synergistically with CXCL12, CCL19 and CCL21, dopamine enhances chemotactic migration of naïve CD8 T cells to the lymph nodes; this can be reversed by a D3 antagonist (Watanabe et al., 2006). Dopamine stimulates T cell activation resulting in TNF α and IL-10 cytokine production from naïve T cells (Besser et al., 2005). By activating T cell D1 receptors, dopamine activates T cells by dampening Treg function (Cosentino et al., 2007). Collectively, these results indicate that dopamine can regulate immune responses.

Dysregulation of the dopamine signalling and abnormal dopamine receptor expression in lymphocytes has been reported in various disease conditions including Alzheimer's disease (Barbanti et al., 2000a), migraine (Barbanti et al., 2000b), schizophrenia (Ilani et al., 2001), multiple sclerosis (Giorelli et al., 2005), and Parkinson's disease (Barbanti et al., 1999). As a result, there are ongoing efforts to develop antagonists and ligands to target dopamine receptors for treatment of neurological disorders (Levite, 2008; Orrego, 1979; Rangel-Gomez and Meeter, 2016; Wilkinson and Brown, 2015). In immunological disorders, there also appears to be role for dopamine. For example,

dopamine enhanced the expansion of Th₁₇ cells in blood from patients with multiple sclerosis (Ferreira et al., 2014) and dysregulation of dopamine has been implicated in the development of autoimmune disorders and proposed as a target for therapy (Levite et al., 2017; Vidal and Pacheco, 2019).

4.3. Acetylcholine

Acetylcholine is a neurotransmitter synthesized in neurons from choline and acetyl-coenzyme A by the enzyme choline acetyltransferase (Baig et al., 2018). In the synaptic cleft, acetylcholine is degraded by acetylcholinesterase to choline and acetate. Acetylcholine signals from neuron to neuron or from neuron to glandular and muscle cells (Baig et al., 2018). Immune cells can interact with cholinergic nerves associated with lymph vessels, or from acetylcholine synthesized by immune cells themselves (D'Andrea et al., 2013).

Choline acetyltransferase has been identified in different immune cells including CD4 and CD8 T cells (Hagforsen et al., 2000; Kawashima et al., 2012; Wessler and Kirkpatrick, 2008) and is responsible for acetylcholine synthesis in T cells and mononuclear leukocytes (Kawashima and Fujii, 2004; Kawashima et al., 2012). Acetylcholine is stored in vesicles, and externalized by exocytosis via acetylcholine vesicular transporters. It is also likely that acetylcholine is synthesized on demand and is directly released without storage (Kawashima et al., 2012). The majority of blood acetylcholine resides within the mononuclear leukocyte fraction, mainly in lymphocytes (Kawashima and Fujii, 2000; Kawashima et al., 2012).

Acetylcholine signals through muscarinic and nicotinic receptors. There are five types of muscarinic receptors (M1–M5) (Abrams and Andersson, 2007). All five muscarinic receptors are found in the CNS, and M1–M4 are additionally expressed in different tissues (Platt and Riedel, 2011). M1 receptors are also found in secretory glands such as salivary, mucosal or sweat glands, M2 in cardiac tissues, and M3 in smooth muscle and secretory glands (Carlson and Kraus, 2018; Cremaschi et al., 2004). Muscarinic receptors are involved in regulation of heart rate, smooth muscle contraction and neural signaling. Nicotinic receptors are ligand-gated ion channels found on muscle and also at certain autonomic ganglia (Skok, 2002; Wang et al., 2002b). The binding of acetylcholine to neuronal nicotinic receptors results in a conformational change and formation of an ion pore that allows the movement of cations, specifically the influx of Ca²⁺ ions that stimulate the release of neurotransmitters (Baig et al., 2018; Cremaschi et al., 2004; Platt and Riedel, 2011).

Muscarinic and nicotinic acetylcholine receptors are expressed on immune cell populations including T and B cells, DCs, and macrophages (Kawashima and Fujii, 2000, 2003; Kawashima et al., 2012). Activation of mouse CD4 T cells increased expression of some nicotinic receptor subtypes ($\alpha 4$ and $\alpha 7$ subunit) suggesting that the expression pattern of nicotinic receptors varies with activation status (Qian et al., 2011). Stimulation of T cells with phorbol 12-myristate 13-acetate (PMA) or phytohemagglutinin (PHA) results in upregulation of choline acetyltransferase and muscarinic M5 receptor genes.

Cholinergic signaling has effects on lymphocyte function. Mice lacking muscarinic M1 receptor showed a defect in early CD8 T cell differentiation into cytolytic T cells when stimulated in vitro (Sinha et al., 2001; Zimring et al., 2005). Nicotine dose-dependently down-regulates gene expression of all nicotinic receptors (Kawashima and Fujii, 2004). These findings suggest that nicotine, and therefore smoking, negatively regulate immune function by suppressing the expression of nicotinic receptors in lymphocytes. Furthermore, in vitro stimulation of muscarinic and nicotinic receptors causes functional and biochemical changes in immune cells. It is therefore likely that acetylcholine released from parasympathetic cholinergic nerve terminals acts on muscarinic and nicotinic receptors on immune cells causing immunosuppressive effects (Fujii et al., 2017b).

Cholinergic pathways in the brain play a role in learning and

memory. During the course of the normal aging process, concentrations of acetylcholine tend to decrease and in Alzheimer's disease, acetylcholine levels can drop significantly (Muir, 1997). Cholinesterase inhibitors are used to treat the symptoms of Alzheimer's disease (Hampel et al., 2019). In the peripheral nervous system, cholinergic transmission is abnormal in myasthenia gravis which arises when the body produces antibodies against nicotinic cholinergic receptors (Drachman et al., 1980). Drugs that inhibit acetylcholinesterase have been shown to be effective in myasthenia gravis (Maggi and Mantegazza, 2011) but little is known about the effects of these therapies on immune function. Given the effects of acetylcholine on immune function, there have been suggestions that targeting the cholinergic system could be a useful approach in treating inflammation (Hoover, 2017) and multiple sclerosis (Di Bari et al., 2017).

4.4. Glutamate

Glutamate is a non-essential amino acid that is synthesized from α -ketoglutarate. Glutamate enters the CNS via a high affinity energy-dependent active transport system (Meldrum, 2000). There are five glutamate transporters in the mammalian CNS. Two of these are found in glia (glial glutamate and aspartate transporter (GLAST) and glial glutamate transporter (GLT)), and three are in neurons (excitatory amino acid carrier 1 (EAAC1), excitatory amino acid transporters-4 and 5 (Meldrum, 2000). Glutamate can also be synthesized from the glutamate-glutamine cycle through the catalytic action of glutaminase. This can occur in presynaptic neurons or non-neuronal glial cells of the central and peripheral nervous system. There are also reports of production of glutamate by lymphocytes (Garg et al., 2008).

Glutamate acts via metabotropic or ionotropic glutamate receptors. Metabotropic glutamate receptor-7 (mGluR7) and mGluR8 are located within the presynaptic grid, mGluR2 and mGluR3 on the pre-terminal axon, and mGluR1/mGluR5 on the perisynaptic glia and astrocytes (Lujan et al., 1996; Meldrum, 2000; Shigemoto et al., 1996). Alternatively, glutamate engages three postsynaptic ionotropic receptors, named after their agonists: N-methyl-D-aspartate (NMDA), α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and kainate. The effects of glutamate activity on the kainate receptor at the presynaptic neuron is inhibitory as it decreases glutamatergic transmission in the hippocampus (Meldrum, 2000; Nedergaard et al., 2002). Glutamate transporters, and receptors including metabotropic receptors mGluR1 and mGluR5, ionotropic receptors AMPA and kainate, are also expressed on immune cells including lymphocytes (BOLDYREV et al., 2012; Ganor and Levite, 2014; Lujan et al., 1996; Meldrum, 2000; Vladychenskaya et al., 2011; Xue and Field, 2011). NMDA receptors are also found on lymphocytes and upregulated after lymphocyte activation (Orihara et al., 2018).

Glutamate has effects on lymphocyte function. Glutamate enhances chemotactic migration of normal naive T cells towards CXCL12 (Ganor et al., 2003), stimulates AMPA receptors on T cells leading to activation, and triggers integrin-dependent adhesion of T cells to laminin and fibronectin (Ganor et al., 2003). NMDA receptor agonists increase Th2 cell activity (Orihara et al., 2018). Glutamate promotes T cell proliferation in response to myelin oligodendrocyte glycoprotein and myelin basic protein, which are antigens implicated in multiple sclerosis (Koehler et al., 2002). Glutamate activates group I metabotropic receptors mGluR1 and mGluR5 promoting intracellular Ca²⁺ mobilization and expression of early inducible genes in T cells (Miglio et al., 2005). Glutamate augments potassium channel Kv1.3 gating potentiating T cell responsiveness to immune stimuli (Levite, 2008). Some of the *ex vivo* studies indicate that glutamate may be immunosuppressive especially at pathophysiological concentrations, since incubation of peripheral human lymphocytes with high concentrations of glutamate decreased the capacity of lymphocytes to respond to stimuli (Lombardi et al., 2001). While these high concentrations might not be achieved in the blood, they could be reached locally in

compartments such as intestinal epithelium and joint synovial fluid, indicating physiological relevance (Ganor and Levite, 2014; Xue and Field, 2011).

High amounts of glutamate are found in the brain of individuals with multiple sclerosis, and this is believed to cause neurotoxicity (Levite, 2008; Meldrum, 2000). In EAE, the animal model of multiple sclerosis, blocking glutamate carboxypeptidase II reduced inflammation (Ha et al., 2016). Glutamate toxicity has also been associated with the ischemic cascade that is associated with spinal cord injury, stroke, traumatic brain injury and other complications of the CNS such as Parkinson's or Alzheimer's disease and amyotrophic lateral sclerosis (Meldrum, 2000). AMPA receptor antagonists are being developed as anti-epileptic medications (Tyrlikova et al., 2018). Glutamate agonists are being developed for use in psychosis (Stone, 2011). It has been proposed that modification of glutamate receptors could be a strategy to control inflammation in autoimmunity (Gammon et al., 2017).

4.5. Gamma-aminobutyric acid (GABA)

GABA is synthesized by decarboxylation of glutamate by the enzyme glutamic acid decarboxylase (GAD). This process includes two GAD isoforms (GAD65 and GAD67) which differ in gene distribution, but also exhibit diverse functions (Erlander et al., 1991; Walls et al., 2011). GABA is widely distributed in the brain, and acts as an inhibitory neurotransmitter (Bloom and Iversen, 1971; Blum and Mann, 2002). In addition to production by the nervous system, T cells and macrophages secrete GABA (Wu et al., 2017).

GABA acts on the GABA_A, GABA_B and GABA_C receptors (Dionisio et al., 2011), which have subunits; for instance, there are 19 GABA_A receptor subunits (Alam et al., 2006; Mendu et al., 2012). In the synaptic cleft, GABA signaling is terminated by reuptake through high-affinity GABA transporters (GAT) in the presynaptic membranes. These transporters include GAT-1, GAT-2, GAT-3 and betaine-GABA transporter (BGT-1). After uptake, GABA is metabolized further by transaminases which terminate GABA signaling (Dionisio et al., 2011; Redecker, 1999). GAT-1 and GAT-3 are expressed in the CNS, while GAT-2 and BGT-1 are found in tissues such as liver, kidney and intestine (9). Thus, GABAergic system mainly includes GAD, GABA-T, GATs, GABA_A and GABA_B receptors (Dionisio et al., 2011; Redecker, 1999; Wu et al., 2017). GABA receptors have been identified on lymphocytes; but their role in regulating functional phenotypes remain scarcely investigated (Alam et al., 2006; Dionisio et al., 2011; Wu et al., 2017). The type and level of expression of these receptors varies widely and may depend on the physiological status of the model under investigation. The GABA receptor subtypes expressed and the levels of expression vary widely on immune cells, and may depend on the disease context under investigation (Barragan et al., 2015; Bhat et al., 2010; Mendu et al., 2011; Mendu et al., 2012).

GABA transporters that play a role in secretion of GABA have been identified in monocytes/macrophages and CD4 T cells (Bhat et al., 2010). GABA transporter GAT-1 is expressed on activated T cells, and inhibits the proliferation of CD4 T cells (Redecker, 1999). Exposure of lymphocytes to GABA reduces T cell proliferation (Bjurstom et al., 2008). GABA signaling regulates the function of antigen presenting cells (APC) inhibiting T cell activation and generation of pro-inflammatory cytokines (Barragan et al., 2015; Bhat et al., 2010). While GABA receptors are expressed in immune cells, their role in regulating functional phenotypes such as migration, proliferation and cytokine production remain scarcely investigated (Alam et al., 2006; Dionisio et al., 2011; Wu et al., 2017).

GABA is involved in the pathogenesis of various disease conditions (Bhat et al., 2010; Prud'homme et al., 2015). GABA is thought to contribute to the pathophysiology of anxiety (Andlin-Sobocki et al., 2005; Wittchen et al., 2005). Increased sensitization of glutamatergic signaling elicits hyper-excitation of neurons and development of epileptogenic seizures (Notenboom et al., 2006). Moreover, dysregulation

in glutamatergic and GABAergic signaling have been linked with neurodegenerative changes associated with cerebral stroke (Lyden et al., 2000). GABA also has a role in immune diseases. GABA is severely decreased in multiple sclerosis patients (Demakova et al., 2003), and increasing the concentration of GABA in the CNS has been shown to improve the outcome of experimental autoimmune encephalomyelitis, a mouse model of multiple sclerosis (Bhat et al., 2010). GABA treatment decreases inflammation associated with rheumatoid arthritis (Tian et al., 2011) and delays the onset of type 1 diabetes (Tian et al., 2004). GABA agonists are in clinical use in the treatment of spasticity (Mondrup and Pedersen, 1984). Drugs that act on GABA receptors are being developed for anxiety (Chen et al., 2018) and in anesthesia (Brohan and Goudra, 2017).

4.6. Serotonin

Serotonin, also known as 5-hydroxytryptamine (5-HT), is a hormone and a neurotransmitter. 5-HT is derived from tryptophan by the actions of tryptophan hydroxylase (Walther and Bader, 2003), with tryptophan converted to 5-hydroxytryptophan which is further decarboxylated to 5-HT (Ahern, 2011). 5-HT is packaged into vesicles by vesicular monoamine transporter in neuroendocrine cells (Weihe et al., 1994). 5-HT can be secreted into the bloodstream where it is taken up by circulating platelets and stored at high concentrations (Walther et al., 2003). Platelets release 5-HT upon activation, dramatically increasing plasma 5-HT concentrations (McNicol and Israels, 1999). 5-HT exhibits autocrine and paracrine effects in the gut, brain and other organs (Saudou and Hen, 1994; Shajib and Khan, 2015; Tork, 1990). In the brain, serotonin is produced by the raphe nuclei and has effects of mood and cognition (Leiser et al., 2015; Olivier, 2015). In addition, serotonin can be produced by lymphocytes (Young et al., 1993).

Approximately 18 genes encode at least 15 5-HT receptors. These receptors have been categorized into 7 subfamilies (5-HT₁-7). Except for 5-HT₃, which is a ligand-gated channel, these receptors are G-protein coupled (Baloira et al., 2012; Giannaccini et al., 2011). Serotonin receptors are expressed in immune cells and have immunoregulatory effects on monocytes, lymphocytes, mast cells and platelets (Ahern, 2011). 5-HT receptors expressed in lymphocytes include 5HT₁, 5HT_{1A}, 5-HT_{1B}, 5-HT_{2A}, 5-HT₃, 5-HT_{3A} and 5-HT₇. Activation of 5-HT₂ receptors on T-cells by mast cell-derived 5-HT, results in delayed-type hypersensitivity (Mossner and Lesch, 1998; Rivera-Baltanas et al., 2014; Shajib and Khan, 2015). Similarly, platelet-secreted 5-HT initiates T cell-dependent contact sensitivity via immunoglobulin E (IgE) (Matsuda et al., 1997). 5-HT potentiates T cell proliferation and activity including cytokine production (IL-16, IL-2), intracellular Na⁺ influx, phosphorylation of ERK1/2 in naive T cells and increased CD4/CD8 ratio (Mossner and Lesch, 1998). Stimulation of 5-HT_{1A} receptors increases survival and S-phase transition of T cells (Abdough et al., 2004). Naive T cells mainly express 5-HT₇ which enhances T cell activation upon stimulation by 5-HT (Leon-Ponte et al., 2007). On other hand, 5-HT_{2A} is mostly expressed on activated T cells and suppresses CD4 T cell activation (Nau Jr et al., 2015).

Alteration in 5-HT physiology is associated with anxiety and depressive disorders (Freitas-Ferrari et al., 2010). Individuals with obsessive-compulsive disorder have reduced 5-HT transporter (5-HTT) levels and 5-HT_{2A} with decreased binding capabilities (Hesse et al., 2005; Perani et al., 2008). 5-HT receptors are altered in patients with depression (Rivera-Baltanas et al., 2014). 5-HT_{2A} is highly expressed in peripheral lymphocytes and the CNS (Inoue et al., 2011; Pandey et al., 1990). Lower levels of 5-HT_{2A} receptor binding has been shown in autistic male patients (Murphy et al., 2006), and decreased levels of 5-HT transporter in the medial frontal cortex of children with autism (Makkonen et al., 2008). In schizophrenia, the serotonergic pathway interacts with the dopaminergic pathway to exacerbate the outcome (Kapur and Remington, 1996), but as yet no significant changes have been observed in 5-HT receptors or 5-HTT expression among

schizophrenic subjects (Frankle et al., 2005). 5-HT has been associated with inflammatory conditions of the gut like inflammatory bowel disease (Manocha and Khan, 2012). Many common medications act on the serotonergic system (for example, selective serotonin reuptake inhibitors), and it is thought that these cause immune suppression, although larger systematic studies are required to confirm this (Eyre et al., 2016). Fluoxetine, a selective serotonin reuptake inhibitor, can suppress experimental autoimmune encephalomyelitis (Bhat et al., 2017).

4.7. Substance P

Substance P is a peptide primarily produced by sensory neurons, and found in the brainstem and dorsal horns of the spinal cord, but also more widely in the brain (Chang and Leeman, 1970; Johnson et al., 2016). It is encoded by the TAC1 gene and is a member of the tachykinin peptide hormone family (Severini et al., 2002). TAC1 also encodes other three neuropeptides — neurokinin A, neuropeptide K, and neuropeptide γ (Severini et al., 2002) that will not be described in this review. Substance P is the most extensively studied mediator of nociceptive stimuli, neuroimmunoregulation and neurogenic inflammation (Carraway and Leeman, 1979; Krause et al., 1992; Severini et al., 2002). There are some reports of production of substance P by lymphocytes (Lambrecht et al., 1999; Zhang et al., 2017).

Substance P binds to cell surface receptors of the neurokinin (NK) family. These G protein-coupled receptors include NK1, NK2 and NK3 (Hafidi et al., 2002; Harrison et al., 2004). Of these, NK1 has high affinity for substance P, and is the best characterised (Bright et al., 2017; Monastyrskaya et al., 2005). NK1 is expressed in neurons (Todd et al., 2000), endothelial cells (Greeno et al., 1993), smooth muscle cells (Maghni et al., 2003), fibroblasts (Liu et al., 2006) and epithelial cells (Bockmann, 2002). Activation of NK1 leads to stimulation of phospholipase C and adenylate cyclase that generate second messengers including diacylglycerol (DAG), inositol trisphosphate (IP3), and cyclic AMP. These second messengers are responsible for intracellular signaling that regulates gene expression. NK1 is expressed by immune cells including NK cells (Feistritzer et al., 2003), eosinophils, mast cells (van der Kleij et al., 2003), T and B cells (Payan et al., 1983), macrophages (Germonpre et al., 1999), dendritic cells (Marriott and Bost, 2001), microglia and astrocytes (Chauhan et al., 2008).

Activation of NK1 receptor on lymphocytes regulates T cell proliferation, differentiation and production of cytokines (Chang and Leeman, 1970; Kang et al., 2004; Krause et al., 1992; Lai et al., 1998; Levite, 2008; Liu et al., 2006; Mantyh, 1991; Payan et al., 1983). Substance P also regulates the proliferation of bone marrow mononuclear cells (Kang et al., 2004; Mantyh, 1991; Payan et al., 1983). Substance P enhances T cell adhesion to lymphocyte function-associated antigen 1 (LFA-1) and ICAM-1 on endothelial cells enhancing T cell chemotaxis. Further, substance P induces migration of innate immune cells including neutrophils by stimulating synthesis of cytokines including macrophage inflammatory proteins (MIP-1 β or CCL4), CCL5, monocyte chemoattractant protein-1 (MCP-1 or CCL2), and CXCL2, as well as expression of cytokine receptors (Kang et al., 2004; Mashaghi et al., 2016).

In disease states, substance P can regulate the immune response by skewing the inflammatory response toward T_H17, T_H1 or T_H2 depending on the context (Cunin et al., 2011; Levite, 1998). Substance P is thought to contribute to the maintenance of inflammation during the chronic phase of multiple sclerosis by promoting extensive infiltration of the CNS by macrophages, dendritic cells, T cells and other immune cells (Hickey, 1999; Whitney et al., 2009). Trauma and infections of the CNS are associated with elevated pro-inflammatory cytokines (Ziebell and Morganti-Kossmann, 2010), and immunomodulatory neuropeptides including substance P (Ho et al., 1997). The non-peptide tachykinin antagonist, CP-96,345, has been shown to downregulate T_H1-type cytokines and improve the outcome of multiple sclerosis (Hafidi et al.,

2002; Harrison et al., 2004; Monastyrskaya et al., 2005). Substance P increases pain under pathological conditions by recruiting glial cells to the site of injury (Grace et al., 2014). For instance, pain after bone fracture has been linked to increased expression of glial activation markers, which is alleviated by antagonizing NK1 (Li et al., 2015). In Parkinson's disease, substance P increases microglial and astrocyte activation and through mechanisms that are suppressed by NK1 antagonists (Barker, 1986). Substance P can enhance blood-brain barrier permeability by disrupting endothelial cell-cell tight junctions, resulting in oedema particularly during traumatic brain or spinal cord injury and stroke (Lewis et al., 2013). This has led to interest in targeting substance P receptors as therapy (Grace et al., 2014; Lewis et al., 2013; Li et al., 2015), and the development of an NK1 agonist as a treatment for nausea after chemotherapy (Aapro et al., 2015).

4.8. Calcitonin gene-related peptide (CGRP)

Calcitonin gene related peptide (CGRP) belongs to the calcitonin family and exists in two isoforms in humans (α -CGRP and β -CGRP) (Russell et al., 2014). α -CGRP is formed from tissue-specific alternative splicing of the primary mRNA transcript of the calcitonin gene (Amara et al., 1982), while β -CGRP is encoded by a pseudogene (Rezaeian et al., 2009). β -CGRP is the least studied in humans. α -CGRP is mainly released from the central and peripheral nervous systems, while β -CGRP is produced by the immune system, pituitary gland and gut. Afferent nerve fibers that produce CGRP are abundant in non-inflamed lymphoid organs including bone marrow, thymus and lymph nodes, but are poorly distributed in the spleen, lung and the gut (Weihe et al., 1991). CGRP-containing nerve fibers are present in the paracortex of lymph nodes, and appear to establish direct contacts with macrophages, mast cells and DCs in the skin (Hosoi et al., 1993; Stead et al., 1987; Weihe et al., 1991). There have been reports of production of CGRP by lymphocytes (Wang et al., 2002a; Xing et al., 2000). T cells treated with mitogens (Wang et al., 2002a) or B cells stimulated with nerve growth factor (NGF) show increased CGRP production. Indeed neutralization of NGF inhibits the synthesis of CGRP from macrophages and B cells indicating the role of NGF in CGRP synthesis (Bracci-Laudiero et al., 2002). CGRP binds to calcitonin-receptor like receptors (CLR) (Russell et al., 2014). Both local and systemic CGRP levels increase during inflammation (e.g. neurogenic inflammation) and are responsible for transmission of pain, for example in migraine. There are CGRP receptors on lymphocytes (McGillis et al., 1991). Binding of CGRP to receptors on lymphocytes leads to increased CAMP levels (Wang et al., 1992).

Treatment of cells and experimental animals with CGRP inhibits the effector function of different immune cells (Assas et al., 2014; Benemei et al., 2009). CGRP decreases the expression of MHC class II, CD86 (a costimulatory receptor) and a panel of cytokines including CCL4, TNF α and IL-1 β by APC (Asahina et al., 1995; Harzenetter et al., 2007; Tokoyoda et al., 2004). Consistent with these studies, *in vivo* administration of CGRP attenuates cutaneous inflammation induced by inflammatory agents (Clementi et al., 1994; Kitazawa and Streilein, 2000).

CGRP could impact the adaptive immune response by promoting chemotaxis of T cells and APC to sites of inflammation. CGRP enhances T cell adhesion to fibronectin (Levite et al., 1998). CGRP induces migration of immature dendritic cells, CD4 and CD8 T cells, but not B cells or mature dendritic cells (Dunzendorfer et al., 2001; Talme et al., 2008). CGRP is also an inhibitor of APC thereby impacting T cell activity (Asahina et al., 1995; Fox et al., 1997). T_H1 cells stimulated with APC pre-treated with CGRP have impaired capacity to secrete CXCL9, CXCL10 and IFN- γ , but the same APC enhance the ability of T_H2 cells to produce CCL17, CCL22 and IL-4 (Ding et al., 2008). CGRP also selectively reduces IFN- γ secretion by CD4 T cells but promotes IL-4 production (Tokoyoda et al., 2004). However, when CD4 T cells are stimulated with anti-CD3, CGRP impairs IL-4 release, but enhances IL-4

production when CD4 T cells are stimulated with anti-CD28.

CGRP stimulates the release of IL-13 from lymphocytes derived from patients with allergic dermatitis (Antunez et al., 2009). CGRP inhibits the production of pro-inflammatory cytokines IL-1 β , TNF α , IL-12p40 and CCL4 from peripheral mononuclear cells including monocytes and dendritic cells (Harzenetter et al., 2007; Torii et al., 1997). Moreover, endothelial cells exposed to increasing concentrations of CGRP exhibit decreased expression of chemokines CXCL1, CCL2 and CXCL8, and reduced ability to chemoattract leukocytes (Huang et al., 2011). Indeed, CGRP treatment protects mice with endotoxemia (Gomes et al., 2005) and liver injury (Kroeger et al., 2009).

In non-obese diabetic (NOD) mice expressing a human CGRP transgene in pancreatic beta cells, local production of CGRP strongly attenuated infiltration of immune cells into islets, and decreased the incidence of insulin-dependent diabetes mellitus (Khachatryan et al., 1997). Moreover, in a rat model of inflammatory bowel disease and experimental colitis, neutralization of CGRP accentuated disease (Reinshagen et al., 1998; Reinshagen et al., 2000). In experimental autoimmune encephalomyelitis, CGRP reduces inflammation (Rossetti et al., 2018). Taken together, these studies indicate that CGRP plays a role as an anti-inflammatory mediator responsible for preventing tissue damage during inflammation or injury. Monoclonal antibodies directed against CGRP are now available for the treatment of migraine (Tso and Goadsby, 2017). The effects of these therapies on lymphocyte function are presently unknown.

4.9. Endocannabinoids

Endocannabinoids are bioactive lipids found widely in the brain (Lu and Mackie, 2016). The first identified endocannabinoid was anandamide (Devane et al., 1992). Activated T and B lymphocytes also produce endocannabinoids (Patti et al., 2016; Sido et al., 2016). Endocannabinoids have physiological effects on the immune system, metabolism and locomotion (Haugh et al., 2016; Thompson et al., 2016). Cannabinoids act on CB1 and CB2 receptors (Cabral et al., 2015; Haugh et al., 2016), which are the targets of cannabis that is used recreationally or medically. Cannabinoid receptors are expressed in the ventral tegmental area and play a role in drug-seeking behavior (Chen et al., 2017). CB2 cannabinoid receptors are expressed in cells of the immune system (Haugh et al., 2016; Malfitano et al., 2014).

Cannabinoids suppress autoreactive lymphocytes (Dittel, 2008) and T cell function (Cencioni et al., 2010). Cannabinoids induce functional Treg cells in vitro (Dhital et al., 2017). In a mouse model of inflammatory bowel disease, a CB2 agonist enhanced differentiation of Treg cells and suppressed disease (Gentili et al., 2018). Recreational users of cannabis have been shown to have suppression of T cell activity (Pacifci et al., 2003). There is current interest in the medical use of cannabinoids (Fraguas-Sanchez and Torres-Suarez, 2018; Olah et al., 2017), including for immunosuppression in autoimmune disease (Katchan et al., 2016). In particular there have been suggestions for the use of cannabinoids in rheumatic disease (Katz-Talmor et al., 2018) and type 1 diabetes (Lehmann et al., 2016). In multiple sclerosis, cannabinoids are approved for the treatment of spasticity, but do not affect disease activity (Zajicek et al., 2005). However cannabinoids affect numerous pathways and further investigation has been recommended (Baker et al., 2007).

4.10. Endorphins

Endorphins are peptides that act as endogenous opioids. There are four families of endorphins; the best known are beta-endorphins and the enkephalins (Corder et al., 2018). Beta-endorphin is produced by the pituitary gland, whereas enkephalins are produced more widely in the brain (Henry et al., 2017). Endorphins play a role in the response to pain and modulate the response to stress (Ironside et al., 2018). Endorphins are produced after exercise and social laughter (Manninen

et al., 2017). Lymphocytes also produce opioids that contribute to analgesia at sites of inflammation (Hua, 2016). Endorphins act on opioid receptors (μ , δ , κ and nociceptin) of which the μ receptor (the morphine receptor) is best known (Corder et al., 2018; Pasternak, 2018; Valentino and Volkow, 2018). There are opioid receptors on lymphocytes and the effect of opioids on lymphocytes is immune suppressive (Brack et al., 2011; Cechova et al., 2018).

There are suggestions that production of β -endorphins could regulate autoimmunity (Morch and Pedersen, 1995). This has been used as a rationale for the use of low dose naltrexone by practitioners of alternative medicine (Li et al., 2018). There have also been suggestions that endorphins can play a role in prevention of carcinogenesis (Zhang et al., 2015). Opioids are widely used in the treatment of pain, sometimes on a chronic basis, and in the community. The overall effect of chronic opioid use on the immune system is thought to be immune suppressive (Roy et al., 2011) although the details are complex (Liang et al., 2016).

4.11. Adenosine

Adenosine is a purine nucleoside, formed from the breakdown of adenosine triphosphate (ATP) (Ernst et al., 2010). ATP is hydrolyzed to adenosine diphosphate (ADP), which is further dephosphorylated to adenosine monophosphate (AMP). Cellular ADP and AMP can be re-phosphorylated in the mitochondria in a process that requires molecular oxygen (North, 2016). However, in hypoxic environments some AMP is dephosphorylated to adenosine by cell membrane-associated nucleotidases. Adenosine is stored and exocytosed by different cells including neurons, microglia and astrocytes. It is not released as a typical neurotransmitter, but rather as a by-product of metabolic activity, through nucleoside transporters (Yao et al., 2011).

Adenosine binds to four G-protein coupled adenosine receptors A1, A2A, A2B and A3. A2A is the major receptor subtype on lymphocytes (Cekic and Linden, 2014; Di Virgilio and Adinolfi, 2017). By binding to adenosine type 2A receptors in coronary vascular smooth muscle cells, adenosine induces smooth muscle relaxation. Moreover, adenosine is a neuromodulator that promotes sleep and suppresses wake-up cycles (Costa and Biaggioni, 1998; Di Virgilio and Adinolfi, 2017). In the extracellular space, adenosine engages purine P1 and P2 receptors on neuronal and non-neuronal cells like endothelial cells, oligodendrocytes and microglia cells promoting various cellular functions (Fields, 2011; Fields and Burnstock, 2006; George et al., 2015).

Activation of A2A on T cells and iNKT cells prevents production of pro-inflammatory cytokines (Lappas et al., 2005; Ohta et al., 2009). Adenosine signaling via A2B on the high endothelial venules (HEV) restricts lymphocyte migration across HEV, but also activation of A2B on APC negatively regulate T cell activation. Engagement of A2A suppresses the expression of intercellular adhesion molecule 1 (ICAM-1) on lymphocytes, IFN γ production and chemotactic factors severely attenuating lymphocyte extravasation into inflamed tissues. By ligating A2A, adenosine regulates T cell receptor (TCR) activation via the adenylylate cyclase/cyclic AMP axis and protein kinase A activities. Protein kinase A can control TCR signaling by phosphorylating downstream molecules including the cyclic AMP response element binding protein (CREB), C-terminal Src kinases and nuclear factor of activated T cells (NF-AT). Protein kinase A may also promote or diminish T cell survival depending on the strength and duration of TCR signal (Linden and Cekic, 2012).

In Alzheimer's disease, there is loss of the A1 adenosine receptor in the hippocampus (Stone et al., 2009). Cerebral ischemia is a condition with a decrease in blood supply to the brain, that can be attenuated by "ischemic pre-conditioning". Adenosine plays a neuroprotective role during the initial phases of ischemic pre-conditioning, (Gidday, 2006). A2A is highly expressed in striatopallidal neurons, and adenosine signaling can regulate neurotransmission in the basal ganglia (Schwarzschild et al., 2006). Antagonizing A2A slows the progression of

Parkinson's disease (Antonelli et al., 2006; Schwarzschild et al., 2006; Stasi et al., 2015), demonstrating the potential for drug discovery by targeting the adenosine pathway. Adenosine is produced in high concentrations in tumours, where it can suppress the immune response; there are currently clinical trials of adenosine antagonists in cancer immunotherapy (Gaudreau et al., 2016; Leone and Emens, 2018). There are also reports of the use of adenosine receptor antagonist for treatment of psychosis (Asaoka et al., 2019).

5. Discussion

This review has summarized evidence that lymphocytes express receptors for neurotransmitters and neurochemicals, and that stimulation by neurotransmitters and neurochemicals affects lymphocyte function (Table 1). Neurotransmitter receptor expression on lymphocytes permits signals from the brain to influence the immune system, via the peripheral nervous system. In addition to effects on lymphocytes, other immune cells have receptors for neurotransmitters and neurochemicals, indicating that neural signaling regulates multiple aspects of the immune response. We have outlined how lymphocytes interact with circulating neurotransmitters and neurochemicals, as well as neurotransmitters released from nerve fibers within lymphoid organs (Felten and Felten, 1988; Sloan et al., 2007). This allows regulation of immunity in response to a changing external environment, including circadian responses to light changes and regulation of homeostasis in response to acute injury and both psychological and physiological stress (Nissen et al., 2018; Scheiermann et al., 2013; Sloan et al., 2010).

The findings described here provide a physiological framework for understanding how factors including stress and pain impact disease, and imply that neural-immune communication may be targeted to enhance immunity. It also provides a theoretical basis for the possible effects of behavioral interventions such as meditation, which modify neurotransmitter levels and affect the immune system, although randomized trials suggest that more work in this field is required (Black and Slavich, 2016). The role of neurotransmitter signaling to the immune system is currently being explored in cancer, where multiple clinical studies are evaluating the effect of β -blockers – which stop norepinephrine signaling to β -adrenergic receptors – on long-term cancer outcomes including metastasis and recurrence (Hiller et al., 2018). As immunotherapy is increasingly included in cancer treatment regimes, neural regulation of immunity may be harnessed to enhance immunotherapy treatment response.

The ability of neurotransmitters and neurochemicals to influence lymphocytes has other implications. Neurotransmitter function is regulated by drugs that are used as treatment for diverse diseases (see Table 1). These drugs are often used over extended periods, raising the possibility of long-term effects on immune function. Future studies are warranted to explore the significance of treatment-induced neural modulation of immunity. It is also plausible that neurotransmitter signalling could be targeted to modulate immune function. In addition to ongoing trials in cancer that are described above, this approach could be useful in autoimmune diseases where new therapies are required, and in the perioperative period where surgery-induced immune response may slow recovery (Hiller et al., 2018; Marik and Flemmer, 2012). In this study, we have highlighted the extensive role for neurotransmitters in lymphocyte biology and show the importance of neurotransmitters in regulation of immunity, as well as the potential for leveraging neurotransmitter activity for therapy.

Acknowledgments

EKS is supported by National Health and Medical Research Council APP1147498.

References

- Aapro, M., Carides, A., Rapoport, B.L., Schmoll, H.J., Zhang, L., Warr, D., 2015. Aprepitant and fosaprepitant: a 10-year review of efficacy and safety. *Oncologist* 20, 450–458.
- Abdoun, M., Albert, P.R., Drobetsky, E., Filep, J.G., Kouassi, E., 2004. 5-HT_{1A}-mediated promotion of mitogen-activated T and B cell survival and proliferation is associated with increased translocation of NF- κ B to the nucleus. *Brain Behav. Immun.* 18, 24–34.
- Abrams, P., Andersson, K.E., 2007. Muscarinic receptor antagonists for overactive bladder. *BJU Int.* 100, 987–1006.
- Ackerman, K.D., Felten, S.Y., Bellinger, D.L., Felten, D.L., 1987. Noradrenergic sympathetic innervation of the spleen: III. Development of innervation in the rat spleen. *J. Neurosci. Res.* 18, 49–54, 123–5.
- Agac, D., Estrada, L.D., Maples, R., Hooper, L.V., Farrar, J.D., 2018. The beta2-adrenergic receptor controls inflammation by driving rapid IL-10 secretion. *Brain Behav. Immun.* 74, 176–185.
- Ahern, G.P., 2011. 5-HT and the immune system. *Curr. Opin. Pharmacol.* 11, 29–33.
- Alam, S., Laughton, D.L., Walding, A., Wolstenholme, A.J., 2006. Human peripheral blood mononuclear cells express GABAA receptor subunits. *Mol. Immunol.* 43, 1432–1442.
- Alberio, T., Pippione, A.C., Comi, C., Oliati, S., Cecconi, D., Zibetti, M., et al., 2012. Dopaminergic therapies modulate the T-CELL proteome of patients with Parkinson's disease. *IUBMB Life* 64, 846–852.
- al-Shawaf, A.A., Kendall, M.D., Cowen, T., 1991. Identification of neural profiles containing vasoactive intestinal polypeptide, acetylcholinesterase and catecholamines in the rat thymus. *J. Anat.* 174, 131–143.
- Amara, S.G., Jonas, V., Rosenfeld, M.G., Ong, E.S., Evans, R.M., 1982. Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. *Nature* 298, 240–244.
- Andlin-Sobocki, P., Jonsson, B., Wittchen, H.U., Olesen, J., 2005. Cost of disorders of the brain in Europe. *Eur. J. Neurol.* 12 (Suppl. 1), 1–27.
- Antonelli, T., Fuxe, K., Agnati, L., Mazzoni, E., Tanganelli, S., Tomasini, M.C., et al., 2006. Experimental studies and theoretical aspects on A2A/D2 receptor interactions in a model of Parkinson's disease. Relevance for L-dopa induced dyskinesias. *J. Neurol. Sci.* 248, 16–22.
- Antunez, C., Torres, M.J., Lopez, S., Rodriguez-Pena, R., Blanca, M., Mayorga, C., et al., 2009. Calcitonin gene-related peptide modulates interleukin-13 in circulating cutaneous lymphocyte-associated antigen-positive T cells in patients with atopic dermatitis. *Br. J. Dermatol.* 161, 547–553.
- Arnason, B.G., Brown, M., Maselli, R., Karaszewski, J., Reder, A., 1988. Blood lymphocyte beta-adrenergic receptors in multiple sclerosis. *Ann. N. Y. Acad. Sci.* 540, 585–588.
- Asahina, A., Moro, O., Hosoi, J., Lerner, E.A., Xu, S., Takashima, A., et al., 1995. Specific induction of cAMP in Langerhans cells by calcitonin gene-related peptide: relevance to functional effects. *Proc. Natl. Acad. Sci. U. S. A.* 92, 8323–8327.
- Asaoka, N., Nishitani, N., Kinoshita, H., Nagai, Y., Hatakama, H., Nagayasu, K., et al., 2019. An adenosine A2A receptor antagonist improves multiple symptoms of repeated quinpirole-induced psychosis. *eNeuro* 6.
- Assas, B.M., Pennock, J.I., Miyan, J.A., 2014. Calcitonin gene-related peptide is a key neurotransmitter in the neuro-immune axis. *Front. Neurosci.* 8, 23.
- Baerwald, C.G., Laufenberg, M., Specht, T., von Wichert, P., Burmester, G.R., Krause, A., 1997. Impaired sympathetic influence on the immune response in patients with rheumatoid arthritis due to lymphocyte subset-specific modulation of beta 2-adrenergic receptors. *Br. J. Rheumatol.* 36, 1262–1269.
- Baig, A.M., Rana, Z., Tariq, S., Lalani, S., Ahmad, H.R., 2018. Traced on the timeline: discovery of acetylcholine and the components of the human cholinergic system in a primitive unicellular Eukaryote *Acanthamoeba* spp. *ACS Chem. Neurosci.* 9, 494–504.
- Baker, D., Jackson, S.J., Pryce, G., 2007. Cannabinoid control of neuroinflammation related to multiple sclerosis. *Br. J. Pharmacol.* 152, 649–654.
- Baloira, A., Nunez, M., Cifrian, J., Vilarino, C., Ojeda, M., Valverde, D., 2012. Polymorphisms in the serotonin transporter protein (SERT) gene in patients with pulmonary arterial hypertension. *Arch. Bronconeumol.* 48, 77–80.
- Barbanti, P., Fabbri, G., Ricci, A., Cerbo, R., Bronzetti, E., Caronti, B., et al., 1999. Increased expression of dopamine receptors on lymphocytes in Parkinson's disease. *Mov. Disord.* 14, 764–771.
- Barbanti, P., Fabbri, G., Ricci, A., Bruno, G., Cerbo, R., Bronzetti, E., et al., 2000a. Reduced density of dopamine D2-like receptors on peripheral blood lymphocytes in Alzheimer's disease. *Mech. Ageing Dev.* 120, 65–75.
- Barbanti, P., Fabbri, G., Ricci, A., Pascali, M.P., Bronzetti, E., Amenta, F., et al., 2000b. Migraine patients show an increased density of dopamine D3 and D4 receptors on lymphocytes. *Cephalalgia* 20, 15–19.
- Barker, R., 1986. Substance P and Parkinson's disease: a causal relationship? *J. Theor. Biol.* 120, 353–362.
- Barragan, A., Weidner, J.M., Jin, Z., Korpi, E.R., Birnir, B., 2015. GABAergic signalling in the immune system. *Acta Phys. (Oxford, England)* 213, 819–827.
- Bellinger DL, Felten SY, Collier TJ, Felten DL. Noradrenergic sympathetic innervation of the spleen: IV. Morphometric analysis in adult and aged F344 rats. *J. Neurosci. Res.* 1987;18:55–63, 126–9.
- Bellinger, D.L., Lorton, D., Hamill, R.W., Felten, S.Y., Felten, D.L., 1993. Acetylcholinesterase staining and choline acetyltransferase activity in the young adult rat spleen: lack of evidence for cholinergic innervation. *Brain Behav. Immun.* 7, 191–204.
- Bellinger, D.L., Millar, B.A., Perez, S., Carter, J., Wood, C., ThyagaRajan, S., et al., 2008. Sympathetic modulation of immunity: relevance to disease. *Cell. Immunol.* 252,

- 27–56.
- Benemei, S., Nicoletti, P., Capone, J.G., Geppetti, P., 2009. CGRP receptors in the control of pain and inflammation. *Curr. Opin. Pharmacol.* 9, 9–14.
- Ben-Shaanan, T.L., Azulay-Debbay, H., Dubovik, T., Starosvetsky, E., Korin, B., Schiller, M., et al., 2016. Activation of the reward system boosts innate and adaptive immunity. *Nat. Med.* 22, 940–944.
- Ben-Shaanan, T.L., Schiller, M., Azulay-Debbay, H., Korin, B., Boshnak, N., Koren, T., et al., 2018. Modulation of anti-tumor immunity by the brain's reward system. *Nat. Commun.* 9, 2723.
- Bergquist, J., Tarkowski, A., Ekman, R., Ewing, A., 1994. Discovery of endogenous catecholamines in lymphocytes and evidence for catecholamine regulation of lymphocyte function via an autocrine loop. *Proc. Natl. Acad. Sci. U. S. A.* 91, 12912–12916.
- Besser, M.J., Ganor, Y., Levite, M., 2005. Dopamine by itself activates either D2, D3 or D1/D5 dopaminergic receptors in normal human T-cells and triggers the selective secretion of either IL-10, TNF α or both. *J. Neuroimmunol.* 169, 161–171.
- Bhat, R., Axtell, R., Mitra, A., Miranda, M., Lock, C., Tsien, R.W., et al., 2010. Inhibitory role for GABA in autoimmune inflammation. *Proc. Natl. Acad. Sci. U. S. A.* 107, 2580–2585.
- Bhat, R., Mahapatra, S., Axtell, R.C., Steinman, L., 2017. Amelioration of ongoing experimental autoimmune encephalomyelitis with fluoxetine. *J. Neuroimmunol.* 313, 77–81.
- Bidlack, J.M., 2000. Detection and function of opioid receptors on cells from the immune system. *Clin. Diagn. Lab. Immunol.* 7, 719–723.
- Bjurstrom, H., Wang, J., Ericsson, I., Bengtsson, M., Liu, Y., Kumar-Mendu, S., et al., 2008. GABA, a natural immunomodulator of T lymphocytes. *J. Neuroimmunol.* 205, 44–50.
- Black, D.S., Slavich, G.M., 2016. Mindfulness meditation and the immune system: a systematic review of randomized controlled trials. *Ann. N. Y. Acad. Sci.* 1373, 13–24.
- Bloom, F.E., Iversen, L.L., 1971. Localizing 3H-GABA in nerve terminals of rat cerebral cortex by electron microscopic autoradiography. *Nature* 229, 628–630.
- Blum, B.P., Mann, J.J., 2002. The GABAergic system in schizophrenia. *Int. J. Neuropsychopharmacol.* 5, 159–179.
- Bockmann, S., 2002. Substance P (NK1) receptor expression by human colonic epithelial cell line Caco-2. *Peptides* 23, 1783–1791.
- Boldyrev, A.A., Bryushkova, E.A., Vladychenskaya, E.A., 2012. NMDA receptors in immune competent cells. *Biochemistry (Mosc)* 77, 128–134.
- Bracci-Laudiero, L., Aloe, L., Buanne, P., Finn, A., Stenfors, C., Vigneti, E., et al., 2002. NGF modulates CGRP synthesis in human B-lymphocytes: a possible anti-inflammatory action of NGF? *J. Neuroimmunol.* 123, 58–65.
- Brack, A., Rittner, H.L., Stein, C., 2011. Immunosuppressive effects of opioids—clinical relevance. *J. Neuroimmune Pharmacol.* 6, 490–502 the official journal of the Society on Neuroimmune Pharmacology.
- Bright, F.M., Vink, R., Byard, R.W., Duncan, J.R., Krous, H.F., Paterson, D.S., 2017. Abnormalities in substance P neurokinin-1 receptor binding in key brainstem nuclei in sudden infant death syndrome related to prematurity and sex. *PLoS One* 12, e0184958.
- Brohan, J., Goudra, B.G., 2017. The role of GABA receptor agonists in anesthesia and sedation. *CNS Drugs* 31, 845–856.
- Bucsek, M.J., Qiao, G., MacDonald, C.R., Giridharan, T., Evans, L., Niedzwecki, B., et al., 2017. beta-adrenergic signaling in mice housed at standard temperatures suppresses an effector phenotype in CD8(+) T cells and undermines checkpoint inhibitor therapy. *Cancer Res.* 77, 5639–5651.
- Burn, J.H., Hutcheon, D.E., Parker, R.H., 1950. Adrenaline and noradrenaline in the suprarenal medulla after insulin. *Br. J. Pharmacol. Chemother.* 5, 417–423.
- Cabral, G.A., Ferreira, G.A., Jamerson, M.J., 2015. Endocannabinoids and the immune system in health and disease. *Handb. Exp. Pharmacol.* 231, 185–211.
- Calvo, W., 1968. The innervation of the bone marrow in laboratory animals. *Am. J. Anat.* 123, 315–328.
- Carlson, A.B., Kraus, G.P., 2018. Physiology, Cholinergic Receptors. StatPearls. Treasure Island (FL).
- Carraway, R., Leeman, S.E., 1979. The amino acid sequence of bovine hypothalamic substance P. Identity to substance P from colliculi and small intestine. *J. Biol. Chem.* 254, 2944–2945.
- Cavallotti, C., Artico, M., Cavallotti, D., 1999. Occurrence of adrenergic nerve fibers and of noradrenaline in thymus gland of juvenile and aged rats. *Immunol. Lett.* 70, 53–62.
- Cechova, K., Hlouskova, M., Javorkova, E., Roubalova, L., Ujickova, H., Holan, V., Svoboda, P., 2018. Up-regulation of μ , δ - and κ -opioid receptors in concanavalin A-stimulated rat spleen lymphocytes. *J. Neuroimmunol.* 321, 12–23.
- Cekic, C., Linden, J., 2014. Adenosine A2A receptors intrinsically regulate CD8+ T cells in the tumor microenvironment. *Cancer Res.* 74, 7239–7249.
- Cencioni, M.T., Chirchui, V., Catanzaro, G., Borsellino, G., Bernardi, G., Battistini, L., et al., 2010. Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors. *PLoS One* 5, e8688.
- Chang, M.M., Leeman, S.E., 1970. Isolation of a sialogenic peptide from bovine hypothalamic tissue and its characterization as substance P. *J. Biol. Chem.* 245, 4784–4790.
- Chauhan, V.S., Sterka Jr., D.G., Gray, D.L., Bost, K.L., Marriott, I., 2008. Neurogenic exacerbation of microglial and astrocyte responses to *Neisseria meningitidis* and *Borrelia burgdorferi*. *J. Immunol.* 180, 8241–8249.
- Chavan, S.S., Pavlov, V.A., Tracey, K.J., 2017. Mechanisms and therapeutic relevance of neuro-immune communication. *Immunity* 46, 927–942.
- Chen, Y., Leon-Ponte, M., Pingle, S.C., O'Connell, P.J., Ahern, G.P., 2015. T lymphocytes possess the machinery for 5-HT synthesis, storage, degradation and release. *Acta Physiol (Oxford)* 213, 860–867.
- Chen, D.J., Gao, M., Gao, F.F., Su, Q.X., Wu, J., 2017. Brain cannabinoid receptor 2: expression, function and modulation. *Acta Pharmacol. Sin.* 38, 312–316.
- Chen, X., van Gerven, J., Cohen, A., Jacobs, G., 2018. Human pharmacology of positive GABA-A subtype-selective receptor modulators for the treatment of anxiety. *Acta Pharmacol. Sin.* <https://doi.org/10.1038/s41401-018-0185-5>. (epub on Dec 5 2018).
- Chirchui, V., 2016. Endocannabinoids and Immunity. *Cannabis Cannabinoid Res.* 1, 59–66.
- Clementi, G., Amico-Roxas, M., Caruso, A., Catena Cutuli, V.M., Prato, A., Maugeri, S., et al., 1994. Effects of CGRP in different models of mouse ear inflammation. *Life Sci.* 54, PL119–24.
- Corder, G., Castro, D.C., Bruchas, M.R., Scherrer, G., 2018. Endogenous and exogenous opioids in pain. *Annu. Rev. Neurosci.* 41, 453–473.
- Cosentino, M., Fietta, A.M., Ferrari, M., Rasini, E., Bombelli, R., Carcano, E., et al., 2007. Human CD4+CD25+ regulatory T cells selectively express tyrosine hydroxylase and contain endogenous catecholamines subserving an autocrine/paracrine inhibitory functional loop. *Blood* 109, 632–642.
- Costa, F., Biaggioni, I., 1998. Role of nitric oxide in adenosine-induced vasodilation in humans. *Hypertension* 31, 1061–1064.
- Cremaschi, G., Fernandez, M.M., Gorelik, G., Goin, J.C., Fossati, C.A., Zwirner, N.W., et al., 2004. Modulatory effects on myocardial physiology induced by an anti-Trypanosoma cruzi monoclonal antibody involve recognition of major antigenic epitopes from beta1-adrenergic and M2-muscarinic cholinergic receptors without requiring receptor cross-linking. *J. Neuroimmunol.* 153, 99–107.
- Cunin, P., Caillon, A., Corvaisier, M., Garo, E., Scotet, M., Blanchard, S., et al., 2011. The tachykinins substance P and hemokinin-1 favor the generation of human memory Th17 cells by inducing IL-1 β , IL-23, and TNF-like 1A expression by monocytes. *J. Immunol.* 186, 4175–4182.
- D'Andrea, V., Bianchi, E., Taurone, S., Mignini, F., Cavallotti, C., Artico, M., 2013. Cholinergic innervation of human mesenteric lymphatic vessels. *Folia Morphol. (Warsz)* 72, 322–327.
- de Diego, A.M., Gandia, L., Garcia, A.G., 2008. A physiological view of the central and peripheral mechanisms that regulate the release of catecholamines at the adrenal medulla. *Acta Physiol (Oxford)* 192, 287–301.
- Demakova, E.V., Korobov, V.P., Lemkina, L.M., 2003. Determination of gamma-aminobutyric acid concentration and activity of glutamate decarboxylase in blood serum of patients with multiple sclerosis. *Klin. Lab. Diagn.* 15–17.
- Devane, W.A., Hanus, L., Breuer, A., Pertwee, R.G., Stevenson, L.A., Griffin, G., et al., 1992. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. *Science (New York, N.Y.)* 258, 1946–1949.
- Dhital, S., Stokes, J.V., Park, N., Seo, K.S., Kaplan, B.L., 2017. Cannabidiol (CBD) induces functional Tregs in response to low-level T cell activation. *Cell. Immunol.* 312, 25–34.
- Di Bari, M., Di Pinto, G., Reale, M., Mengod, G., Tata, A.M., 2017. Cholinergic system and neuroinflammation: implication in multiple sclerosis. *Cent. Nerv. Syst. Agents Med. Chem.* 17, 109–115.
- Di Virgilio, F., Adinolfi, E., 2017. Extracellular purines, purinergic receptors and tumor growth. *Oncogene* 36, 293–303.
- Ding, W., Stohl, L.L., Wagner, J.A., Granstein, R.D., 2008. Calcitonin gene-related peptide biases Langerhans cells toward Th2-type immunity. *J. Immunol.* 181, 6020–6026.
- Dionisio, L., Jose De Rosa, M., Bouzat, C., Esandi Mdell, C., 2011. An intrinsic GABAergic system in human lymphocytes. *Neuropharmacology* 60, 513–519.
- Dittel, B.N., 2008. Direct suppression of autoreactive lymphocytes in the central nervous system via the CB2 receptor. *Br. J. Pharmacol.* 153, 271–276.
- Drachman, D.B., Adams, R.N., Stanley, E.F., Pestronk, A., 1980. Mechanisms of acetylcholine receptor loss in myasthenia gravis. *J. Neurol. Neurosurg. Psychiatry* 43, 601–610.
- Dubin, A.E., Patapoutian, A., 2010. Nociceptors: the sensors of the pain pathway. *J. Clin. Invest.* 120, 3760–3772.
- Dunzendorfer, S., Kaser, A., Meierhofer, C., Tilg, H., Wiedermann, C.J., 2001. Cutting edge: peripheral neuropeptides attract immature and arrest mature blood-derived dendritic cells. *J. Immunol.* 166, 2167–2172.
- Dutcher, J.M., Creswell, J.D., 2018. The role of brain reward pathways in stress resilience and health. *Neurosci. Biobehav. Rev.* 95, 559–567.
- Elenkov, I.J., Wilder, R.L., Chrousos, G.P., Vizi, E.S., 2000. The sympathetic nerve—an integrative interface between two supersystems: the brain and the immune system. *Pharmacol. Rev.* 52, 595–638.
- Eriksson, M., Lindh, B., Uvnäs-Moberg, K., Hokfelt, T., 1996. Distribution and origin of peptide-containing nerve fibres in the rat and human mammary gland. *Neuroscience* 70, 227–245.
- Erlander, M.G., Tillakaratne, N.J., Feldblum, S., Patel, N., Tobin, A.J., 1991. Two genes encode distinct glutamate decarboxylases. *Neuron* 7, 91–100.
- Ernst, P.B., Garrison, J.C., Thompson, L.F., 2010. Much ado about adenosine: adenosine synthesis and function in regulatory T cell biology. *J. Immunol.* 185, 1993–1998.
- Esler, M., Jennings, G., Korner, P., Willett, I., Dudley, F., Hasking, G., et al., 1988. Assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover. *Hypertension* 11, 3–20.
- Esler, M., Jennings, G., Lambert, G., Meredith, I., Horne, M., Eisenhofer, G., 1990. Overflow of catecholamine neurotransmitters to the circulation: source, fate, and functions. *Physiol. Rev.* 70, 963–985.
- Eyre, H.A., Lavretsky, H., Kartika, J., Qassim, A., Baune, B.T., 2016. Modulatory effects of antidepressant classes on the innate and adaptive immune system in depression. *Pharmacopsychiatry* 49, 85–96.
- Fallarino, F., Volpi, C., Fazio, F., Notartomaso, S., Vacca, C., Busceti, C., et al., 2010. Metabotropic glutamate receptor-4 modulates adaptive immunity and restrains neuroinflammation. *Nat. Med.* 16, 897–902.
- Feistritz, C., Clausen, J., Sturn, D.H., Djanani, A., Gunsilius, E., Wiedermann, C.J., et al., 2003. Natural killer cell functions mediated by the neuropeptide substance P. *Regul. Pept.* 116, 119–126.
- Felten, D.L., Felten, S.Y., 1988. Sympathetic noradrenergic innervation of immune

- organs. *Brain Behav. Immun.* 2, 293–300.
- Felten, S.Y., Olschowka, J., 1987. Noradrenergic sympathetic innervation of the spleen: II. Tyrosine hydroxylase (TH)-positive nerve terminals form synapticlike contacts on lymphocytes in the splenic white pulp. *J. Neurosci. Res.* 18, 37–48.
- Felten, D.L., Livnat, S., Felten, S.Y., Carlson, S.L., Bellinger, D.L., Yeh, P., 1984. Sympathetic innervation of lymph nodes in mice. *Brain Res. Bull.* 13, 693–699.
- Felten, D.L., Felten, S.Y., Carlson, S.L., Olschowka, J.A., Livnat, S., 1985. Noradrenergic and peptidergic innervation of lymphoid tissue. *J. Immunol.* 135, 755–765.
- Felten DL, Ackerman KD, Wiegand SJ, Felten SY. Noradrenergic sympathetic innervation of the spleen: I. Nerve fibers associate with lymphocytes and macrophages in specific compartments of the splenic white pulp. *J. Neurosci. Res.* 1987;18:28-36, 118-21.
- Felten, D.L., Felten, S.Y., Bellinger, D.L., Madden, K.S., 1993. Fundamental aspects of neural-immune signaling. *Psychother. Psychosom.* 60, 46–56.
- Ferreira, T.B., Barros, P.O., Teixeira, B., Cassano, T., Centurio, N., Kasahara, T.M., et al., 2014. Dopamine favors expansion of glucocorticoid-resistant IL-17-producing T cells in multiple sclerosis. *Brain Behav. Immun.* 41, 182–190.
- Fields, R.D., 2011. Nonsynaptic and nonvesicular ATP release from neurons and relevance to neuron-glia signaling. *Semin. Cell Dev. Biol.* 22, 214–219.
- Fields, R.D., Burnstock, G., 2006. Purinergic signalling in neuron-glia interactions. *Nat. Rev. Neurosci.* 7, 423–436.
- Fink, T., Weihe, E., 1988. Multiple neuropeptides in nerves supplying mammalian lymph nodes: messenger candidates for sensory and autonomic neuroimmunomodulation? *Neurosci. Lett.* 90, 39–44.
- Fox, F.E., Kubin, M., Cassin, M., Niu, Z., Hosoi, J., Torii, H., et al., 1997. Calcitonin gene-related peptide inhibits proliferation and antigen presentation by human peripheral blood mononuclear cells: effects on B7, interleukin 10, and interleukin 12. *J. Invest. Dermatol.* 108, 43–48.
- Fraguas-Sanchez, A.I., Torres-Suarez, A.I., 2018. Medical use of cannabinoids. *Drugs* 78, 1665–1703.
- Frankle, W.G., Narendran, R., Huang, Y., Hwang, D.R., Lombardo, I., Cangiano, C., et al., 2005. Serotonin transporter availability in patients with schizophrenia: a positron emission tomography imaging study with [¹¹C]DASB. *Biol. Psychiatry* 57, 1510–1516.
- Freitas-Ferrari, M.C., Hallak, J.E., Trzesniak, C., Filho, A.S., Machado-de-Sousa, J.P., Chagas, M.H., et al., 2010. Neuroimaging in social anxiety disorder: a systematic review of the literature. *Prog. Neuro-Psychopharmacol. Biol. Psychiatry* 34, 565–580.
- Fujii, T., Mashimo, M., Moriwaki, Y., Misawa, H., Ono, S., Horiguchi, K., et al., 2017a. Expression and function of the cholinergic system in immune cells. *Front. Immunol.* 8, 1085.
- Fujii, T., Mashimo, M., Moriwaki, Y., Misawa, H., Ono, S., Horiguchi, K., et al., 2017b. Physiological functions of the cholinergic system in immune cells. *J. Pharmacol. Sci.* 134, 1–21.
- Furlan, A., La Manno, G., Lubke, M., Haring, M., Abdo, H., Hochgerner, H., et al., 2016. Visceral motor neuron diversity delineates a cellular basis for nipple- and pilo-erection muscle control. *Nat. Neurosci.* 19, 1331–1340.
- Gammon, J.M., Adapa, A.R., Jewell, C.M., 2017. Control of autoimmune inflammation using liposomes to deliver positive allosteric modulators of metabotropic glutamate receptors. *J. Biomed. Mater. Res. A* 105, 2977–2985.
- Ganor, Y., Levite, M., 2014. The neurotransmitter glutamate and human T cells: glutamate receptors and glutamate-induced direct and potent effects on normal human T cells, cancerous human leukemia and lymphoma T cells, and autoimmune human T cells. *J. Neural Transm.* 121, 983–1006 (Vienna, Austria : 1996).
- Ganor, Y., Besser, M., Ben-Zakay, N., Unger, T., Levite, M., 2003. Human T cells express a functional ionotropic glutamate receptor GluR3, and glutamate by itself triggers integrin-mediated adhesion to laminin and fibronectin and chemotactic migration. *J. Immunol.* 170, 4362–4372.
- Garg, S.K., Banerjee, R., Kipnis, J., 2008. Neuroprotective immunity: T cell-derived glutamate endows astrocytes with a neuroprotective phenotype. *J. Immunol.* 180, 3866–3873.
- Gaudreau, P.O., Allard, B., Turcotte, M., Stagg, J., 2016. CD73-adenosine reduces immune responses and survival in ovarian cancer patients. *Oncoimmunology* 5, e1127496.
- Gentili, M., Ronchetti, S., Ricci, E., Di Paola, R., Gugliandolo, E., Cuzzocrea, S., et al., 2018. Selective CB2 inverse agonist JTE907 drives T cell differentiation towards a Treg cell phenotype and ameliorates inflammation in a mouse model of inflammatory bowel disease. *Pharmacol. Res.* 141, 21–31.
- George, J., Goncalves, F.Q., Cristovao, G., Rodrigues, L., Meyer Fernandes, J.R., Goncalves, T., et al., 2015. Different danger signals differently impact on microglial proliferation through alterations of ATP release and extracellular metabolism. *Glia* 63, 1636–1645.
- Germonpre, P.R., Bullock, G.R., Lambrecht, B.N., Van De Velde, V., Luyten, W.H., Joos, G.F., et al., 1999. Presence of substance P and neurokinin 1 receptors in human sputum macrophages and U-937 cells. *Eur. Respir. J.* 14, 776–782.
- Giannaccini, G., Betti, L., Palego, L., Pirone, A., Schmid, L., Lanza, M., et al., 2011. Serotonin transporter (SERT) and translocator protein (TSPO) expression in the obese ob/ob mouse. *BMC Neurosci.* 12, 18.
- Giddy, J.M., 2006. Cerebral preconditioning and ischaemic tolerance. *Nat. Rev. Neurosci.* 7, 437–448.
- Giorelli, M., Livrea, P., Trojano, M., 2005. Dopamine fails to regulate activation of peripheral blood lymphocytes from multiple sclerosis patients: effects of IFN-beta. *J. Interf. Cytokine Res.* 25, 395–406.
- Gomes, R.N., Castro-Faria-Neto, H.C., Bozza, P.T., Soares, M.B., Shoemaker, C.B., David, J.R., et al., 2005. Calcitonin gene-related peptide inhibits local acute inflammation and protects mice against lethal endotoxemia. *Shock* 24, 590–594.
- Grace, P.M., Hutchinson, M.R., Maier, S.F., Watkins, L.R., 2014. Pathological pain and the neuroimmune interface. *Nat. Rev. Immunol.* 14, 217–231.
- Greeno, E.W., Mantyh, P., Vercellotti, G.M., Moldow, C.F., 1993. Functional neurokinin 1 receptors for substance P are expressed by human vascular endothelium. *J. Exp. Med.* 177, 1269–1276.
- Ha, D., Bing, S.J., Ahn, G., Kim, J., Cho, J., Kim, A., et al., 2016. Blocking glutamate carboxypeptidase II inhibits glutamate excitotoxicity and regulates immune responses in experimental autoimmune encephalomyelitis. *FEBS J.* 283, 3438–3456.
- Hafidi, A., Beurg, M., Bouleau, Y., Dulon, D., 2002. Comparative distribution of NK1, NK2, and NK3 receptors in the rat brainstem auditory nuclei. *Brain Res.* 947, 299–306.
- Hagforsen, E., Einarsson, A., Aronsson, F., Nordlind, K., Michaelsson, G., 2000. The distribution of choline acetyltransferase- and acetylcholinesterase-like immunoreactivity in the palmar skin of patients with palmoplantar pustulosis. *Br. J. Dermatol.* 142, 234–242.
- Hampel, H., Mesulam, M.M., Cuello, A.C., Khachaturian, A.S., Vergallo, A., Farlow, M.R., et al., 2019. Revisiting the cholinergic hypothesis in Alzheimer's disease: emerging evidence from translational and clinical research. *J. Prevent. Alzheimer's Dis.* 6, 2–15.
- Harrison, T.A., Hoover, D.B., King, M.S., 2004. Distinct regional distributions of NK1 and NK3 neurokinin receptor immunoreactivity in rat brainstem gustatory centers. *Brain Res. Bull.* 63, 7–17.
- Harzenetter, M.D., Novotny, A.R., Gais, P., Molina, C.A., Altmayr, F., Holzmann, B., 2007. Negative regulation of TLR responses by the neuropeptide CGRP is mediated by the transcriptional repressor ICER. *J. Immunol.* 179, 607–615.
- Hasko, G., Linden, J., Cronstein, B., Pacher, P., 2008. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. *Nat. Rev. Drug Discov.* 7, 759–770.
- Haugh, O., Penman, J., Irving, A.J., Campbell, V.A., 2016. The emerging role of the cannabinoid receptor family in peripheral and neuro-immune interactions. *Curr. Drug Targets* 17, 1834–1840.
- Henry, M.S., Gendron, L., Tremblay, M.E., Drolet, G., 2017. Enkephalins: endogenous analgesics with an emerging role in stress resilience. *Neural Plast.* 2017, 1546125.
- Herr, N., Bode, C., Duerschmied, D., 2017. The effects of serotonin in immune cells. *Front. Cardiovasc. Med.* 4, 48.
- Hesse, S., Muller, U., Lincke, T., Barthel, H., Villmann, T., Angermeyer, M.C., et al., 2005. Serotonin and dopamine transporter imaging in patients with obsessive-compulsive disorder. *Psychiatry Res.* 140, 63–72.
- Hickey, W.F., 1999. Leukocyte traffic in the central nervous system: the participants and their roles. *Semin. Immunol.* 11, 125–137.
- Hiller, J.G., Perry, N.J., Poulgiannis, G., Riedel, B., Sloan, E.K., 2018. Perioperative events influence cancer recurrence risk after surgery. *Nat. Rev. Clin. Oncol.* 15, 205–218.
- Ho, W.Z., Lai, J.P., Zhu, X.H., Uvaydova, M., Douglas, S.D., 1997. Human monocytes and macrophages express substance P and neurokinin-1 receptor. *J. Immunol.* 159, 5654–5660.
- Holzmann, B., 2013. Modulation of immune responses by the neuropeptide CGRP. *Amino Acids* 45, 1–7.
- Hoover, D.B., 2017. Cholinergic modulation of the immune system presents new approaches for treating inflammation. *Pharmacol. Ther.* 179, 1–16.
- Hosoi, J., Murphy, G.F., Egan, C.L., Lerner, E.A., Grabbe, S., Asahina, A., et al., 1993. Regulation of Langerhans cell function by nerves containing calcitonin gene-related peptide. *Nature* 363, 159–163.
- Hua, S., 2016. Neuroimmune interaction in the regulation of peripheral opioid-mediated analgesia in inflammation. *Front. Immunol.* 7, 293.
- Huang, J., Stohl, L.L., Zhou, X., Ding, W., Granstein, R.D., 2011. Calcitonin gene-related peptide inhibits chemokine production by human dermal microvascular endothelial cells. *Brain Behav. Immun.* 25, 787–799.
- Ilani, T., Ben-Shachar, D., Strous, R.D., Mazor, M., Sheinkman, A., Kotler, M., et al., 2001. A peripheral marker for schizophrenia: increased levels of D3 dopamine receptor mRNA in blood lymphocytes. *Proc. Natl. Acad. Sci. U. S. A.* 98, 625–628.
- Inoue, M., Okazaki, T., Kitazono, T., Mizushima, M., Omata, M., Ozaki, S., 2011. Regulation of antigen-specific CTL and Th1 cell activation through 5-Hydroxytryptamine 2A receptor. *Int. Immunopharmacol.* 11, 67–73.
- Ironsides, M., Kumar, P., Kang, M.S., Pizzagalli, D.A., 2018. Brain mechanisms mediating effects of stress on reward sensitivity. *Curr. Opin. Behav. Sci.* 22, 106–113.
- Jin, Z., Mendu, S.K., Birnir, B., 2013. GABA is an effective immunomodulatory molecule. *Amino Acids* 45, 87–94.
- Johnson, M.B., Young, A.D., Marriott, I., 2016. The therapeutic potential of targeting substance P/NK-1R interactions in inflammatory CNS disorders. *Front. Cell. Neurosci.* 10, 296.
- Kang, H.S., Trzaska, K.A., Corcoran, K., Chang, V.T., Rameshwar, P., 2004. Neurokinin receptors: relevance to the emerging immune system. *Arch. Immunol. Ther. Exp. (Warsz)* 52, 338–347.
- Kapur, S., Remington, G., 1996. Serotonin-dopamine interaction and its relevance to schizophrenia. *Am. J. Psychiatry* 153, 466–476.
- Kasanova, Z., Ceccarini, J., Frank, M.J., Amelsvoort, T.V., Booij, J., Heinzel, A., et al., 2017. Striatal dopaminergic modulation of reinforcement learning predicts reward-oriented behavior in daily life. *Biol. Psychol.* 127, 1–9.
- Katayama, Y., Battista, M., Kao, W.M., Hidalgo, A., Peired, A.J., Thomas, S.A., et al., 2006. Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow. *Cell* 124, 407–421.
- Katchan, V., David, P., Shoenfeld, Y., 2016. Cannabinoids and autoimmune diseases: a systematic review. *Autoimmun. Rev.* 15, 513–528.
- Katz-Talmon, D., Katz, I., Porat-Katz, B.S., Shoenfeld, Y., 2018. Cannabinoids for the treatment of rheumatic diseases – where do we stand? *Nat. Rev. Rheumatol.* 14, 488–498.
- Kavalali, E.T., 2015. The mechanisms and functions of spontaneous neurotransmitter release. *Nat. Rev. Neurosci.* 16, 5–16.

- Kawashima, K., Fujii, T., 2000. Extraneuronal cholinergic system in lymphocytes. *Pharmacol. Ther.* 86, 29–48.
- Kawashima, K., Fujii, T., 2003. The lymphocytic cholinergic system and its contribution to the regulation of immune activity. *Life Sci.* 74, 675–696.
- Kawashima, K., Fujii, T., 2004. Expression of non-neuronal acetylcholine in lymphocytes and its contribution to the regulation of immune function. *Front. Biosci.* 9, 2063–2085.
- Kawashima, K., Fujii, T., Moriwaki, Y., Misawa, H., 2012. Critical roles of acetylcholine and the muscarinic and nicotinic acetylcholine receptors in the regulation of immune function. *Life Sci.* 91, 1027–1032.
- Khachatrian, A., Guerdier, S., Palluault, F., Cote, G., Solimena, M., Valentijn, K., et al., 1997. Targeted expression of the neuropeptide calcitonin gene-related peptide to beta cells prevents diabetes in NOD mice. *J. Immunol.* 158, 1409–1416.
- Kitazawa, T., Streilein, J.W., 2000. Hapten-specific tolerance promoted by calcitonin gene-related peptide. *J. Invest. Dermatol.* 115, 942–948.
- Klein, M.O., Battagello, D.S., Cardoso, A.R., Hauser, D.N., Bittencourt, J.C., Correa, R.G., 2019. Dopamine: functions, signaling, and association with neurological diseases. *Cell. Mol. Neurobiol.* 39, 31–59.
- Koehler, N.K., Genain, C.P., Giesser, B., Hauser, S.L., 2002. The human T cell response to myelin oligodendrocyte glycoprotein: a multiple sclerosis family-based study. *J. Immunol.* 168, 5920–5927.
- Krause, J.E., Takeda, Y., Hershey, A.D., 1992. Structure, functions, and mechanisms of substance P receptor action. *J. Invest. Dermatol.* 98, 2s–7s.
- Kroeger, I., Erhardt, A., Abt, D., Fischer, M., Biburger, M., Rau, T., et al., 2009. The neuropeptide calcitonin gene-related peptide (CGRP) prevents inflammatory liver injury in mice. *J. Hepatol.* 51, 342–353.
- Lai, J.P., Douglas, S.D., Ho, W.Z., 1998. Human lymphocytes express substance P and its receptor. *J. Neuroimmunol.* 86, 80–86.
- Lambrecht, B.N., Germonpre, P.R., Everaert, E.G., Carro-Muino, I., De Veerman, M., de Felipe, C., et al., 1999. Endogenously produced substance P contributes to lymphocyte proliferation induced by dendritic cells and direct TCR ligation. *Eur. J. Immunol.* 29, 3815–3825.
- Lappas, C.M., Rieger, J.M., Linden, J., 2005. A2A adenosine receptor induction inhibits IFN-gamma production in murine CD4⁺ T cells. *J. Immunol.* 174, 1073–1080.
- Lehmann, C., Fisher, N.B., Tugwell, B., Szczesniak, A., Kelly, M., Zhou, J., 2016. Experimental cannabidiol treatment reduces early pancreatic inflammation in type 1 diabetes. *Clin. Hemorheol. Microcirc.* 64, 655–662.
- Leiser, S.C., Li, Y., Pehrson, A.L., Dale, E., Smagin, G., Sanchez, C., 2015. Serotonergic regulation of prefrontal cortical circuitries involved in cognitive processing: a review of Individual 5-HT receptor mechanisms and concerted effects of 5-HT receptors exemplified by the multimodal antidepressant vortioxetine. *ACS Chem. Neurosci.* 6, 970–986.
- Leone, R.D., Emens, L.A., 2018. Targeting adenosine for cancer immunotherapy. *J. Immunother. Cancer* 6, 57.
- Leon-Ponte, M., Ahern, G.P., O'Connell, P.J., 2007. Serotonin provides an accessory signal to enhance T-cell activation by signaling through the 5-HT7 receptor. *Blood* 109, 3139–3146.
- Leposavic, G., Pilipovic, I., Perisic, M., 2011. Cellular and nerve fibre catecholaminergic thymic network: steroid hormone dependent activity. *Physiol. Res.* 60 (Suppl. 1), S71–S82.
- Levite, M., 1998. Neuropeptides, by direct interaction with T cells, induce cytokine secretion and break the commitment to a distinct T helper phenotype. *Proc. Natl. Acad. Sci. U. S. A.* 95, 12544–12549.
- Levite, M., 2008. Neurotransmitters activate T-cells and elicit crucial functions via neurotransmitter receptors. *Curr. Opin. Pharmacol.* 8, 460–471.
- Levite, M., 2016. Dopamine and T cells: dopamine receptors and potent effects on T cells, dopamine production in T cells, and abnormalities in the dopaminergic system in T cells in autoimmune, neurological and psychiatric diseases. *Acta Phys. (Oxford, England)* 216, 42–89.
- Levite, M., Cahalon, L., Hershkovitz, R., Steinman, L., Lider, O., 1998. Neuropeptides, via specific receptors, regulate T cell adhesion to fibronectin. *J. Immunol.* 160, 993–1000.
- Levite, M., Chowers, Y., Ganor, Y., Besser, M., Hershkovits, R., Cahalon, L., 2001. Dopamine interacts directly with its D3 and D2 receptors on normal human T cells, and activates beta1 integrin function. *Eur. J. Immunol.* 31, 3504–3512.
- Levite, M., Marino, F., Dopamine, Cosentino M., 2017. T cells and multiple sclerosis (MS). *J. Neural Transm.* 124, 525–542 (Vienna, Austria : 1996).
- Lewis, K.M., Turner, R.J., Vink, R., 2013. Blocking neurogenic inflammation for the treatment of acute disorders of the central nervous system. *Int. J. Inflamm.* 2013, 578480.
- Li, W.W., Guo, T.Z., Shi, X., Sun, Y., Wei, T., Clark, D.J., et al., 2015. Substance P spinal signaling induces glial activation and nociceptive sensitization after fracture. *Neuroscience* 310, 73–90.
- Li, Z., You, Y., Griffin, N., Feng, J., Shan, F., 2018. Low-dose naltrexone (LDN): a promising treatment in immune-related diseases and cancer therapy. *Int. Immunopharmacol.* 61, 178–184.
- Liang, X., Liu, R., Chen, C., Ji, F., Li, T., 2016. Opioid system modulates the immune function: a review. *Transl. Perioper. Pain Med.* 1, 5–13.
- Linden, J., Cecik, C., 2012. Regulation of lymphocyte function by adenosine. *Arterioscler. Thromb. Vasc. Biol.* 32, 2097–2103.
- Liu, J.Y., Hu, J.H., Zhu, Q.G., Li, F.Q., Sun, H.J., 2006. Substance P receptor expression in human skin keratinocytes and fibroblasts. *Br. J. Dermatol.* 155, 657–662.
- Lombardi, G., Dianzani, C., Miglio, G., Canonico, P.L., Fantozzi, R., 2001. Characterization of ionotropic glutamate receptors in human lymphocytes. *Br. J. Pharmacol.* 133, 936–944.
- Lorente, L., Martin, M.M., Almeida, T., Perez-Cejas, A., Ramos, L., Argueso, M., et al., 2016. Serum levels of substance P and mortality in patients with a severe acute ischemic stroke. *Int. J. Mol. Sci.* 17.
- Lu, H.C., Mackie, K., 2016. An introduction to the endogenous cannabinoid system. *Biol. Psychiatry* 79, 516–525.
- Lujan, R., Nusser, Z., Roberts, J.D., Shigemoto, R., Somogyi, P., 1996. Perisynaptic location of metabotropic glutamate receptors mGluR1 and mGluR5 on dendrites and dendritic spines in the rat hippocampus. *Eur. J. Neurosci.* 8, 1488–1500.
- Lyden, P.D., Jackson-Friedman, C., Shin, C., Hassid, S., 2000. Synergistic combinatorial stroke therapy: a quantal bioassay of a GABA agonist and a glutamate antagonist. *Exp. Neurol.* 163, 477–489.
- Madden, K.S., Felten, D.L., 2001. Beta-adrenoceptor blockade alters thymocyte differentiation in aged mice. *Cell. Mol. Biol.* 47, 189–196 (Noisy-le-grand).
- Maggi, L., Mantegazza, R., 2011. Treatment of myasthenia gravis: focus on pyridostigmine. *Clin. Drug Investig.* 31, 691–701.
- Maghni, K., Michoud, M.C., Alles, M., Rubin, A., Govindaraju, V., Meloche, C., et al., 2003. Airway smooth muscle cells express functional neurokinin-1 receptors and the nerve-derived proinflammatory peptide 2 (CB2). *Semin. Immunol.* 26, 369–379.
- Manninen, S., Tuominen, L., Dunbar, R.I., Karjalainen, T., Hirvonen, J., Arponen, E., et al., 2017. Social laughter triggers endogenous opioid release in humans. *J. Neurosci.* 37, 6125–6131.
- Manocha, M., Khan, W.I., 2012. Serotonin and GI disorders: an update on clinical and experimental studies. *Clin. Transl. Gastroenterol.* 3, e13.
- Mantyh, P.W., 1991. Substance P and the inflammatory and immune response. *Ann. N. Y. Acad. Sci.* 632, 263–271.
- Marik, P.E., Flemmer, M., 2012. The immune response to surgery and trauma: implications for treatment. *J. Trauma Acute Care Surg.* 73, 801–808.
- Marino, F., Cosentino, M., 2013. Adrenergic modulation of immune cells: an update. *Amino Acids* 45, 55–71.
- Marriott, I., Bost, K.L., 2001. Expression of authentic substance P receptors in murine and human dendritic cells. *J. Neuroimmunol.* 114, 131–141.
- Mashaghi, A., Marmalidou, A., Tehrani, M., Grace, P.M., Pothoulakis, C., Dana, R., 2016. Neuropeptide substance P and the immune response. *Cell. Mol. Life Sci.: CMLS* 73, 4249–4264.
- Matsuda, H., Ushio, H., Geba, G.P., Askenase, P.W., 1997. Human platelets can initiate T cell-dependent contact sensitivity through local serotonin release mediated by IgE antibodies. *J. Immunol.* 158, 2891–2897.
- McGillis, J.P., Humphreys, S., Reid, S., 1991. Characterization of functional calcitonin gene-related peptide receptors on rat lymphocytes. *J. Immunol.* 147, 3482–3489.
- McNicol, A., Israels, S.J., 1999. Platelet dense granules: structure, function and implications for haemostasis. *Thromb. Res.* 95, 1–18.
- Meldrum, B.S., 2000. Glutamate as a neurotransmitter in the brain: review of physiology and pathology. *J. Nutr.* 130, 1007s–15s.
- Mendu, S.K., Akesson, L., Jin, Z., Edlund, A., Cilio, C., Lernmark, A., et al., 2011. Increased GABA(A) channel subunits expression in CD8(+) but not in CD4(+) T cells in BB rats developing diabetes compared to their congenic littermates. *Mol. Immunol.* 48, 399–407.
- Mendu, S.K., Bhandage, A., Jin, Z., Birnir, B., 2012. Different subtypes of GABA-A receptors are expressed in human, mouse and rat T lymphocytes. *PLoS One* 7, e42959.
- Miglio, G., Varsaldi, F., Dianzani, C., Fantozzi, R., Lombardi, G., 2005. Stimulation of group I metabotropic glutamate receptors evokes calcium signals and c-fos gene expression in human T cells. *Biochem. Pharmacol.* 70, 189–199.
- Mignini, F., Streccioni, V., Amenta, F., 2003. Autonomic innervation of immune organs and neuroimmune modulation. *Auton. Neurosci.* 103, 1–25.
- Mignini, F., Sabbatini, M., Capacchietti, M., Amantini, C., Bianchi, E., Artico, M., et al., 2013. T-cell subpopulations express a different pattern of dopaminergic markers in intra- and extra-thymic compartments. *J. Biol. Regul. Homeost. Agents* 27, 463–475.
- Mikami, N., Matsushita, H., Kato, T., Kawasaki, R., Sawazaki, T., Kishimoto, T., et al., 2011. Calcitonin gene-related peptide is an important regulator of cutaneous immunity: effect on dendritic cell and T cell functions. *J. Immunol.* 186, 6886–6893.
- Missale, C., Nash, S.R., Robinson, S.W., Jaber, M., Caron, M.G., 1998. Dopamine receptors: from structure to function. *Physiol. Rev.* 78, 189–225.
- Monastyrskaya, K., Hostettler, A., Buerki, S., Draeger, A., 2005. The NK1 receptor localizes to the plasma membrane microdomains, and its activation is dependent on lipid raft integrity. *J. Biol. Chem.* 280, 7135–7146.
- Mondrup, K., Pedersen, E., 1984. The clinical effect of the GABA-agonist, progabide, on spasticity. *Acta Neurol. Scand.* 69, 200–206.
- Morch, H., Pedersen, B.K., 1995. Beta-endorphin and the immune system—possible role in autoimmune diseases. *Autoimmunity* 21, 161–171.
- Mossner, R., Lesch, K.P., 1998. Role of serotonin in the immune system and in neuro-immune interactions. *Brain Behav. Immun.* 12, 249–271.
- Muir, J.L., 1997. Acetylcholine, aging, and Alzheimer's disease. *Pharmacol. Biochem. Behav.* 56, 687–696.
- Murphy, D.G., Daly, E., Schmitz, N., Toal, F., Murphy, K., Curran, S., et al., 2006. Cortical serotonin 5-HT2A receptor binding and social communication in adults with Asperger's syndrome: an in vivo SPECT study. *Am. J. Psychiatry* 163, 934–936.
- Nakai, A., Hayano, Y., Furuta, F., Noda, M., Suzuki, K., 2014. Control of lymphocyte egress from lymph nodes through beta2-adrenergic receptors. *J. Exp. Med.* 211, 2583–2598.
- Nance, D.M., Sanders, V.M., 2007. Autonomic innervation and regulation of the immune system (1987–2007). *Brain Behav. Immun.* 21, 736–745.

- Nance, D.M., Hopkins, D.A., Bieger, D., 1987. Re-investigation of the innervation of the thymus gland in mice and rats. *Brain Behav. Immun.* 1, 134–147.
- Nau Jr., F., Miller, J., Saravia, J., Ahlert, T., Yu, B., Happel, K.I., et al., 2015. Serotonin 5-HT₂ receptor activation prevents allergic asthma in a mouse model. *Am. J. Phys. Lung Cell. Mol. Phys.* 308, L191–L198.
- Nedergaard, M., Takano, T., Hansen, A.J., 2002. Beyond the role of glutamate as a neurotransmitter. *Nat. Rev. Neurosci.* 3, 748–755.
- Nissen, M.D., Sloan, E.K., Mattarollo, S.R., 2018. beta-adrenergic signaling impairs antitumor CD8(+) T-cell responses to B-cell lymphoma immunotherapy. *Cancer Immunol. Res.* 6, 98–109.
- North, R.A., 2016. P2X receptors. *Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci.* 371.
- Notenboom, R.G., Hampson, D.R., Jansen, G.H., van Rijen, P.C., van Veelen, C.W., van Nieuwenhuizen, O., et al., 2006. Up-regulation of hippocampal metabotropic glutamate receptor 5 in temporal lobe epilepsy patients. *Brain* 129, 96–107.
- Novotny, G.E., Kliche, K.O., 1986. Innervation of lymph nodes: a combined silver impregnation and electron-microscopic study. *Acta Anat. (Basel)* 127, 243–248.
- Ohta, A., Ohta, A., Madasu, M., Kini, R., Subramanian, M., Goel, N., et al., 2009. A2A adenosine receptor may allow expansion of T cells lacking effector functions in extracellular adenosine-rich microenvironments. *J. Immunol.* 183, 5487–5493.
- Olah, A., Szekanez, Z., Biro, T., 2017. Targeting cannabinoid signaling in the immune system: "high"-ly exciting questions, possibilities, and challenges. *Front. Immunol.* 8, 1487.
- Olivier, B., 2015. Serotonin: a never-ending story. *Eur. J. Pharmacol.* 753, 2–18.
- Orihara, K., Odemuyiwa, S.O., Stefura, W.P., Ilarraz, R., HayGlass, K.T., Moqbel, R., 2018. Neurotransmitter signalling via NMDA receptors leads to decreased T helper type 1-like and enhanced T helper type 2-like immune balance in humans. *Immunology* 153, 368–379.
- Orrego, F., 1979. Criteria for the identification of central neurotransmitters, and their application to studies with some nerve tissue preparations in vitro. *Neuroscience* 4, 1037–1057.
- Pacheco, R., Prado, C.E., Barrientos, M.J., Bernales, S., 2009. Role of dopamine in the physiology of T-cells and dendritic cells. *J. Neuroimmunol.* 216, 8–19.
- Pacheco, R., Contreras, F., Zouali, M., 2014. The dopaminergic system in autoimmune diseases. *Front. Immunol.* 5, 117.
- Pacifici, R., Zuccaro, P., Pichini, S., Roset, P.N., Poudevida, S., Farre, M., et al., 2003. Modulation of the immune system in cannabis users. *Jama* 289, 1929–1931.
- Pandey, G.N., Pandey, S.C., Janicak, P.G., Marks, R.C., Davis, J.M., 1990. Platelet serotonin-2 receptor binding sites in depression and suicide. *Biol. Psychiatry* 28, 215–222.
- Pasternak, G.W., 2018. Mu opioid pharmacology: 40 years to the promised land. *Adv. Pharmacol. (San Diego, Calif.)* 82, 261–291.
- Patti, F., Messina, S., Solaro, C., Amato, M.P., Bergamaschi, R., Bonavita, S., et al., 2016. Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity. *J. Neurol. Neurosurg. Psychiatry* 87, 944–951.
- Payan, D.G., Brewster, D.R., Goetzl, E.J., 1983. Specific stimulation of human T lymphocytes by substance P. *J. Immunol.* 131, 1613–1615.
- Perani, D., Garibotto, V., Gorini, A., Moresco, R.M., Henin, M., Panzacchi, A., et al., 2008. In vivo PET study of 5HT(2A) serotonin and D(2) dopamine dysfunction in drug-naïve obsessive-compulsive disorder. *Neuromig.* 42, 306–314.
- Pham, T.H., Okada, T., Matloubian, M., Lo, C.G., Cyster, J.G., 2008. S1P1 receptor signaling overrides retention mediated by G alpha i-coupled receptors to promote T cell egress. *Immunity* 28, 122–133.
- Pinho-Ribeiro, F.A., Verri Jr., W.A., Chiu, I.M., 2017. Nociceptor sensory neuron-immune interactions in pain and inflammation. *Trends Immunol.* 38, 5–19.
- Platt, B., Riedel, G., 2011. The cholinergic system, EEG and sleep. *Behav. Brain Res.* 221, 499–504.
- Pongratz, G., Straub, R.H., 2014. The sympathetic nervous response in inflammation. *Arthritis Res. Ther.* 16, 504.
- Porterfield, V.M., Gabella, K.M., Simmons, M.A., Johnson, J.D., 2012. Repeated stressor exposure regionally enhances beta-adrenergic receptor-mediated brain IL-1beta production. *Brain Behav. Immun.* 26, 1249–1255.
- Prud'homme, G.J., Glinka, Y., Wang, Q., 2015. Immunological GABAergic interactions and therapeutic applications in autoimmune diseases. *Autoimmun. Rev.* 14, 1048–1056.
- Qian, J., Galitovskiy, V., Chernyavsky, A.I., Marchenko, S., Grando, S.A., 2011. Plasticity of the murine spleen T-cell cholinergic receptors and their role in in vitro differentiation of naïve CD4 T cells toward the Th1, Th2 and Th17 lineages. *Genes Immun.* 12, 222–230.
- Rangel-Gomez, M., Meeter, M., 2016. Neurotransmitters and novelty: a systematic review. *J. Psychopharmacol.* 30, 3–12.
- Redecker, P., 1999. Immunoreactivity for multiple GABA transporters (GAT-1, GAT-2, GAT-3) in the gerbil pineal gland. *Neurosci. Lett.* 266, 117–120.
- Reinshagen, M., Flamig, G., Ernst, S., Geerling, I., Wong, H., Walsh, J.H., et al., 1998. Calcitonin gene-related peptide mediates the protective effect of sensory nerves in a model of colonic injury. *J. Pharmacol. Exp. Ther.* 286, 657–661.
- Reinshagen, M., Rohm, H., Steinkamp, M., Lieb, K., Geerling, I., Von Herbay, A., et al., 2000. Protective role of neurotrophins in experimental inflammation of the rat gut. *Gastroenterology* 119, 368–376.
- Ren, K., Dubner, R., 2010. Interactions between the immune and nervous systems in pain. *Nat. Med.* 16, 1267–1276.
- Rezaeian, A.H., Isokane, T., Nishibori, M., Chiba, M., Hiraiwa, N., Yoshizawa, M., et al., 2009. alphaCGRP and betaCGRP transcript amount in mouse tissues of various developmental stages and their tissue expression sites. *Brain and Development* 31, 682–693.
- Richard, J.M., Castro, D.C., Difeliceantonio, A.G., Robinson, M.J., Berridge, K.C., 2013. Mapping brain circuits of reward and motivation: in the footsteps of Ann Kelley. *Neurosci. Biobehav. Rev.* 37, 1919–1931.
- Rivera-Baltanas, T., Olivares, J.M., Martinez-Villamarin, J.R., Fenton, E.Y., Kalynchuk, L.E., Caruncho, H.J., 2014. Serotonin 2A receptor clustering in peripheral lymphocytes is altered in major depression and may be a biomarker of therapeutic efficacy. *J. Affect. Disord.* 163, 47–55.
- Rossetti, I., Zambusi, L., Finardi, A., Bodini, A., Provini, L., Furlan, R., et al., 2018. Calcitonin gene-related peptide decreases IL-1beta, IL-6 as well as Ym1, Arg1, CD163 expression in a brain tissue context-dependent manner while ameliorating experimental autoimmune encephalomyelitis. *J. Neuroimmunol.* 323, 94–104.
- Roy, S., Ninkovic, J., Banerjee, S., Charboneau, R.G., Das, S., Dutta, R., et al., 2011. Opioid drug abuse and modulation of immune function: consequences in the susceptibility to opportunistic infections. *J. Neuroimmune Pharm.* 6, 442–465.
- Russell, F.A., King, R., Smillie, S.J., Kodji, X., Brain, S.D., 2014. Calcitonin gene-related peptide: physiology and pathophysiology. *Physiol. Rev.* 94, 1099–1142.
- Santambrogio, L., Lipartiti, M., Bruni, A., Dal Toso, R., 1993. Dopamine receptors on human T- and B-lymphocytes. *J. Neuroimmunol.* 45, 113–119.
- Saudou, F., Hen, R., 1994. 5-Hydroxytryptamine receptor subtypes in vertebrates and invertebrates. *Neurochem. Int.* 25, 503–532.
- Scanzano, A., Cosentino, M., 2015. Adrenergic regulation of innate immunity: a review. *Front. Pharmacol.* 6, 171.
- Scheiermann, C., Kunisaki, Y., Lucas, D., Chow, A., Jang, J.E., Zhang, D., et al., 2012. Adrenergic nerves govern circadian leukocyte recruitment to tissues. *Immunity* 37, 290–301.
- Scheiermann, C., Kunisaki, Y., Frenette, P.S., 2013. Circadian control of the immune system. *Nat. Rev. Immunol.* 13, 190–198.
- Schwarzschild, M.A., Agnati, L., Fuxe, K., Chen, J.F., Morelli, M., 2006. Targeting adenosine A2A receptors in Parkinson's disease. *Trends Neurosci.* 29, 647–654.
- Severini, C., Improta, G., Falconieri-Erspamer, G., Salvadori, S., Erspamer, V., 2002. The tachykinin peptide family. *Pharmacol. Rev.* 54, 285–322.
- Shajib, M.S., Khan, W.I., 2015. The role of serotonin and its receptors in activation of immune responses and inflammation. *Acta Physiol (Oxford)* 213, 561–574.
- Shigemoto, R., Kulik, A., Roberts, J.D., Ohishi, H., Nusser, Z., Kaneko, T., et al., 1996. Target-cell-specific concentration of a metabotropic glutamate receptor in the presynaptic active zone. *Nature* 381, 523–525.
- Sido, J.M., Nagarkatti, P.S., Nagarkatti, M., 2016. Production of endocannabinoids by activated T cells and B cells modulates inflammation associated with delayed-type hypersensitivity. *Eur. J. Immunol.* 46, 1472–1479.
- Simonini, M.V., Polak, P.E., Sharp, A., McGuire, S., Galea, E., Feinstein, D.L., 2010. Increasing CNS noradrenaline reduces EAE severity. *J. Neuroimmune Pharm.* 5, 252–259 the official journal of the Society on NeuroImmune Pharmacology.
- Sinha, K., Dannelly, H.K., Ghosh, S.K., 2001. Effects of T-lymphocyte-dependent and -independent immunity on cholinergic enzyme activity in mouse lacrimal gland. *Exp. Physiol.* 86, 169–176.
- Skok, V.I., 2002. Nicotinic acetylcholine receptors in autonomic ganglia. *Auton. Neurosci. Basic Clin.* 97, 1–11.
- Sloan, E.K., Walker, A.K., 2019. Elucidating the mechanisms of psychosocial influences on cancer using preclinical in vivo models. *Curr. Opin. Behav. Sci.* 28, 129–135.
- Sloan, E.K., Tarara, R.P., Capitanio, J.P., Cole, S.W., 2006. Enhanced replication of simian immunodeficiency virus adjacent to catecholaminergic varicosities in primate lymph nodes. *J. Virol.* 80, 4326–4335.
- Sloan, E.K., Capitanio, J.P., Tarara, R.P., Mendoza, S.P., Mason, W.A., Cole, S.W., 2007. Social stress enhances sympathetic innervation of primate lymph nodes: mechanisms and implications for viral pathogenesis. *J. Neurosci.* 27, 8857–8865.
- Sloan, E.K., Priceman, S.J., Cox, B.F., Yu, S., Pimentel, M.A., Tangkanangnukul, V., et al., 2010. The sympathetic nervous system induces a metastatic switch in primary breast cancer. *Cancer Res.* 70, 7042–7052.
- Sneader, W., 2001. The discovery and synthesis of epinephrine. *Drug News Perspect.* 14, 491–494.
- Stasi, M.A., Minetti, P., Lombardo, K., Riccioni, T., Caprioli, A., Vertheby, M., et al., 2015. Animal models of Parkinson's disease: effects of two adenosine A2A receptor antagonists ST4206 and ST3932, metabolites of 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine (ST1535). *Eur. J. Pharmacol.* 761, 353–361.
- Stead, R.H., Tomioka, M., Quinonez, G., Simon, G.T., Felten, S.Y., Bienenstock, J., 1987. Intestinal mucosal mast cells in normal and nematode-infected rat intestines are in intimate contact with peptidergic nerves. *Proc. Natl. Acad. Sci. U. S. A.* 84, 2975–2979.
- Stone, J.M., 2011. Glutamatergic antipsychotic drugs: a new dawn in the treatment of schizophrenia? *Ther. Adv. Psychopharmacol.* 1, 5–18.
- Stone, T.W., Ceruti, S., Abbraccio, M.P., 2009. Adenosine receptors and neurological disease: neuroprotection and neurodegeneration. *Handb. Exp. Pharmacol.* 535–587.
- Straub, R.H., 2004. Complexity of the bi-directional neuroimmune junction in the spleen. *Trends Pharmacol. Sci.* 25, 640–646.
- Talhada, D., Rabenstein, M., Ruscher, K., 2018. The role of dopaminergic immune cell signalling in poststroke inflammation. *Ther. Adv. Neurol. Disord.* 11, 1756286418774225.
- Talme, T., Liu, Z., Sundqvist, K.G., 2008. The neuropeptide calcitonin gene-related peptide (CGRP) stimulates T cell migration into collagen matrices. *J. Neuroimmunol.* 196, 60–66.
- Tfelt-Hansen, P., Le, H., 2009. Calcitonin gene-related peptide in blood: is it increased in the external jugular vein during migraine and cluster headache? A review. *J. Headache Pain* 10, 137–143.
- Thompson, Z., Argueta, D., Garland Jr., T., DiPatrizio, N., 2016. Circulating levels of endocannabinoids respond acutely to voluntary exercise, are altered in mice selectively bred for high voluntary wheel running, and differ between the sexes. *Physiol. Behav.* 170, 141–150.
- Tian, J., Lu, Y., Zhang, H., Chau, C.H., Dang, H.N., Kaufman, D.L., 2004. Gamma-

- aminobutyric acid inhibits T cell autoimmunity and the development of inflammatory responses in a mouse type 1 diabetes model. *J. Immunol.* 173, 5298–5304.
- Tian, J., Yong, J., Dang, H., Kaufman, D.L., 2011. Oral GABA treatment downregulates inflammatory responses in a mouse model of rheumatoid arthritis. *Autoimmunity*. 44, 465–470.
- Todd, A.J., McGill, M.M., Shehab, S.A., 2000. Neurokinin 1 receptor expression by neurons in laminae I, III and IV of the rat spinal dorsal horn that project to the brainstem. *Eur. J. Neurosci.* 12, 689–700.
- Tokoyoda, K., Tsujikawa, K., Matsushita, H., Ono, Y., Hayashi, T., Harada, Y., et al., 2004. Up-regulation of IL-4 production by the activated cAMP/cAMP-dependent protein kinase (protein kinase A) pathway in CD3/CD28-stimulated naive T cells. *Int. Immunol.* 16, 643–653.
- Tollefson, L., Bulloch, K., 1990. Dual-label retrograde transport: CNS innervation of the mouse thymus distinct from other mediastinum viscera. *J. Neurosci. Res.* 25, 20–28.
- Torii, H., Hosoi, J., Beissert, S., Xu, S., Fox, F.E., Asahina, A., et al., 1997. Regulation of cytokine expression in macrophages and the Langerhans cell-like line XS52 by calcitonin gene-related peptide. *J. Leukoc. Biol.* 61, 216–223.
- Tork, I., 1990. Anatomy of the serotonergic system. *Ann. N. Y. Acad. Sci.* 600, 9–34 discussion -5.
- Tso, A.R., Goadsby, P.J., 2017. Anti-CGRP monoclonal antibodies: the next era of migraine prevention? *Curr. Treat. Options Neurol.* 19, 27.
- Tyrlikova, I., Brazdil, M., Rektor, I., Tyrlik, M., 2018. Perampanel as monotherapy and adjunctive therapy for focal onset seizures, focal to bilateral tonic-clonic seizures and as adjunctive therapy for generalized onset tonic-clonic seizures. *Expert. Rev. Neurother.* 1–12.
- Ueda, Y., Kondo, M., Kelsoe, G., 2005. Inflammation and the reciprocal production of granulocytes and lymphocytes in bone marrow. *J. Exp. Med.* 201, 1771–1780.
- Valentino, R.J., Volkow, N.D., 2018. Untangling the complexity of opioid receptor function. *Neuropsychopharmacology* 43, 2514–2520 official publication of the American College of Neuropsychopharmacology.
- van der Kleij, H.P., Ma, D., Redegeld, F.A., Kraneveld, A.D., Nijkamp, F.P., Bienenstock, J., 2003. Functional expression of neurokinin 1 receptors on mast cells induced by IL-4 and stem cell factor. *J. Immunol.* 171, 2074–2079.
- Vidal, P.M., Pacheco, R., 2019. Targeting the dopaminergic system in autoimmunity. *J. Neuroimmune Pharm.* <https://doi.org/10.1007/s11481-019-09834-5>. (epub on Jan 19 2019).
- Vizi, E.S., Elenkov, I.J., 2002. Nonsynaptic noradrenaline release in neuro-immune responses. *Acta Biol. Hung.* 53, 229–244.
- Vladychenskaya, E., Tyulina, O., Urano, S., Boldyrev, A., 2011. Rat lymphocytes express NMDA receptors that take part in regulation of cytokine production. *Cell Biochem. Funct.* 29, 527–533.
- Wahle, M., Kolker, S., Krause, A., Burmester, G.R., Baerwald, C.G., 2001. Impaired catecholaminergic signalling of B lymphocytes in patients with chronic rheumatic diseases. *Ann. Rheum. Dis.* 60, 505–510.
- Wahle, M., Hanefeld, G., Brunn, S., Straub, R.H., Wagner, U., Krause, A., et al., 2006. Failure of catecholamines to shift T-cell cytokine responses toward a Th2 profile in patients with rheumatoid arthritis. *Arthritis Res. Ther.* 8, R138.
- Walls, A.B., Eyjolfsson, E.M., Smeland, O.B., Nilsen, L.H., Schousboe, I., Schousboe, A., et al., 2011. Knockout of GAD65 has major impact on synaptic GABA synthesized from astrocyte-derived glutamine. *J. Cereb. Blood Flow Metab.* 31, 494–503.
- Walther, D.J., Bader, M., 2003. A unique central tryptophan hydroxylase isoform. *Biochem. Pharmacol.* 66, 1673–1680.
- Walther, D.J., Peter, J.U., Bashammakh, S., Hortnagl, H., Voits, M., Fink, H., et al., 2003. Synthesis of serotonin by a second tryptophan hydroxylase isoform. *Science*. 299, 76.
- Wang, F., Millet, I., Bottomly, K., Vignery, A., 1992. Calcitonin gene-related peptide inhibits interleukin 2 production by murine T lymphocytes. *J. Biol. Chem.* 267, 21052–21057.
- Wang, H., Xing, L., Li, W., Hou, L., Guo, J., Wang, X., 2002a. Production and secretion of calcitonin gene-related peptide from human lymphocytes. *J. Neuroimmunol.* 130, 155–162.
- Wang, N., Orr-Urtreger, A., Korczyn, A.D., 2002b. The role of neuronal nicotinic acetylcholine receptor subunits in autonomic ganglia: lessons from knockout mice. *Prog. Neurobiol.* 68, 341–360.
- Wang, G.J., Volkow, N.D., Thanos, P.K., Fowler, J.S., 2009. Imaging of brain dopamine pathways: implications for understanding obesity. *J. Addict. Med.* 3, 8–18.
- Watanabe, M., Kimura, A., Akasaka, K., Hayashi, S., 1986. Determination of acetylcholine in human blood. *Biochem. Med. Metabol. Biol.* 36, 355–362.
- Watanabe, Y., Nakayama, T., Nagakubo, D., Hieshima, K., Jin, Z., Katou, F., et al., 2006. Dopamine selectively induces migration and homing of naive CD8+ T cells via dopamine receptor D3. *J. Immunol.* 176, 848–856.
- Webber, R.H., DeFelice, R., Ferguson, R.J., Powell, J.P., 1970. Bone marrow response to stimulation of the sympathetic trunks in rats. *Acta Anat. (Basel)* 77, 92–97.
- Weihe, E., Nohr, D., Michel, S., Muller, S., Zentel, H.J., Fink, T., et al., 1991. Molecular anatomy of the neuro-immune connection. *Int. J. Neurosci.* 59, 1–23.
- Weihe, E., Schafer, M.K., Erickson, J.D., Eiden, L.E., 1994. Localization of vesicular monoamine transporter isoforms (VMAT1 and VMAT2) to endocrine cells and neurons in rat. *J. Mol. Neurosci.* 5, 149–164.
- Wessler, I., Kirkpatrick, C.J., 2008. Acetylcholine beyond neurons: the non-neuronal cholinergic system in humans. *Br. J. Pharmacol.* 154, 1558–1571.
- Whitney, N.P., Eidem, T.M., Peng, H., Huang, Y., Zheng, J.C., 2009. Inflammation mediates varying effects in neurogenesis: relevance to the pathogenesis of brain injury and neurodegenerative disorders. *J. Neurochem.* 108, 1343–1359.
- Wilkinson, M., Brown, R.E., 2015. Neurotransmitters. In: Wilkinson, M., Brown, R.E. (Eds.), *An Introduction to Neuroendocrinology*. Cambridge University Press, pp. 78–119.
- Wittchen, H.U., Jonsson, B., Olesen, J., 2005. Towards a better understanding of the size and burden and cost of brain disorders in Europe. *Eur. Neuropsychopharmacol.* 15, 355–356.
- Wood, E.J., 2006. Marks' basic medical biochemistry: a clinical approach (second edition). *Biochem. Mol. Biol. Educ.* 34, 395.
- Wu, C., Qin, X., Du, H., Li, N., Ren, W., Peng, Y., 2017. The immunological function of GABAergic system. *Front. Biosci. (Landmark Ed.)* 22, 1162–1172.
- Wu, L., Tai, Y., Hu, S., Zhang, M., Wang, R., Zhou, W., et al., 2018. Bidirectional role of beta2-adrenergic receptor in autoimmune diseases. *Front. Pharmacol.* 9, 1313.
- Xing, L., Guo, J., Wang, X., 2000. Induction and expression of beta-calcitonin gene-related peptide in rat T lymphocytes and its significance. *J. Immunol.* 165, 4359–4366.
- Xue, H., Field, C.J., 2011. New role of glutamate as an immunoregulator via glutamate receptors and transporters. *Front. Biosci. (Schol Ed.)* 3, 1007–1020.
- Yamaguchi, I., Kopin, I.J., 1979. Plasma catecholamine and blood pressure responses to sympathetic stimulation in pithed rats. *Am. J. Phys.* 237, H305–H310.
- Yao, S.Y., Ng, A.M., Cass, C.E., Baldwin, S.A., Young, J.D., 2011. Nucleobase transport by human equilibrative nucleoside transporter 1 (hENT1). *J. Biol. Chem.* 286, 32552–32562.
- Young, M.R., Kut, J.L., Coogan, M.P., Wright, M.A., Young, M.E., Matthews, J., 1993. Stimulation of splenic T-lymphocyte function by endogenous serotonin and by low-dose exogenous serotonin. *Immunology*. 80, 395–400.
- Zajicek, J.P., Sanders, H.P., Wright, D.E., Vickery, P.J., Ingram, W.M., Reilly, S.M., et al., 2005. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. *J. Neurol. Neurosurg. Psychiatry* 76, 1664–1669.
- Zhang, C., Murugan, S., Boyadjieva, N., Jabbar, S., Shrivastava, P., Sarkar, D.K., 2015. Beta-endorphin cell therapy for cancer prevention. *Cancer Prev. Res. (Phila.)* 8, 56–67.
- Zhang, Z., Zheng, W., Xie, H., Chai, R., Wang, J., Zhang, H., et al., 2017. Up-regulated expression of substance P in CD8(+) T cells and NK1R on monocytes of atopic dermatitis. *J. Transl. Med.* 15, 93.
- Ziebell, J.M., Morganti-Kossmann, M.C., 2010. Involvement of pro- and anti-inflammatory cytokines and chemokines in the pathophysiology of traumatic brain injury. *Neurotherapeutics*. 7, 22–30.
- Zimring, J.C., Kapp, L.M., Yamada, M., Wess, J., Kapp, J.A., 2005. Regulation of CD8+ cytolytic T lymphocyte differentiation by a cholinergic pathway. *J. Neuroimmunol.* 164, 66–75.
- Zoukos, Y., Leonard, J.P., Thomaides, T., Thompson, A.J., Cuzner, M.L., 1992. beta-Adrenergic receptor density and function of peripheral blood mononuclear cells are increased in multiple sclerosis: a regulatory role for cortisol and interleukin-1. *Ann. Neurol.* 31, 657.